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1. Zusammenfassung 
Das Wachstum eines Tumors hängt von einer Reihe von limitierenden 
Schritten ab, die in höchstem Masse von der Mikroumgebung des Tumors 
beeinflusst werden. In diesem Zusammenhang gelten Tumor-assoziierte 
Makrophagen (TAM) als hauptsächliche Regulatoren des Tumorwachstums; dies 
einerseits wegen deren Einfluss auf die Angiogenese, auf den sogenannten 
„angiogenic switch“, und andererseits wegen deren vielfältigen Funktionen im 
Modellieren der Tumormikroumgebung. Diese Ereignisse erleichtern und 
orchestrieren die Invasion und Verbreitung von Tumorzellen ins benachbarte 
Gewebe, weshalb man auch begünstigende Effekte der TAM auf die Bildung von 
Metastasen vermutet. Ihr genauer Einfluss in diesen komplexen Prozessen ist 
allerdings noch nicht vollständig aufgeklärt. 
Schon früher haben wir und andere die vielseitige Rolle von TAM im 
Tumorwachstum studiert, indem wir TAM in Tumor tragenden Mäusen mit einer 
pharmakologischen Methode depletierten. Diese Studien haben erfolgreich eine 
kausale Verbindung zwischen TAM Depletion und reduziertem Tumorwachstum 
hergestellt, wobei die TAM-abhängige Tumorangiogenese als hauptsächlicher 
Mechanismus identifiziert wurde. In der präsentierten Arbeit habe ich diese auf 
Bisphosphonat-Liposomen basierte Technik der TAM Depletion im F9-Terato-
karzinom Mausmodell angewendet, und mit Hilfe einer Genexpressionsanalyse 
dieser Tumore Genprofile identifiziert, welche zusätzliche und neuartige Rollen für 
TAM in Tumorwachstum und -entwicklung aufdeckten. 
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Resultate dieser Analyse haben eine Korrelation zwischen TAM-Dichte und einem 
Genprofil ergeben, das der sogenannten epithelial-mesenchymalen-Transition (EMT) 
entspricht. EMT ist ein gut charakterisierter Mechanismus, durch welchen 
epithelartige Tumorzellen einen invasiven mesenchymalen Phänotyp erlangen 
können, der als limitierender Schritt in der Tumorinvasion und Metastasierung 
betrachtet wird. Die gefundene Korrelation zwischen TAM-Dichte und EMT-
assoziiertem Genprofil suggeriert demzufolge eine Rolle der TAM in der Regulation 
der EMT-assoziierten Tumorinvasion. Dieser Befund wurde weiter in Zellkulturen von 
F9- und NMuMG-Zellen und mit molekularen und zellbiologischen Techniken 
untersucht.  Dabei wurde der TAM-abhängige Faktor TGF-β1, und die durch diesen 
Faktor induzierte Aktivierung der β-Catenin Signalkaskade, als Hauptmechanismus 
der Tumorzell-EMT identifiziert. 
Die TAM-induzierte EMT führte zu erhöhter Tumorzellinvasion als Antwort auf 
Makrophagen abhängige Chemokine. Die Invasion wurde jedoch nach 
Neutralisierung von TGF-β1 wieder aufgehoben. TGF-β1 alleine erwies sich nicht als 
genügend starkes Chemoattraktans für die untersuchten Zelllinien. Demzufolge 
zeigen die Daten einen direkten Einfluss der TAM auf die intrinsische Regulierung 
invasiver Eigenschaften von Tumorzellen. TAM sind eine wichtige Quelle 
verschiedenster Faktoren, wie z.B. SDF-1, VEGF und EGF und die Ergebnisse 
suggerieren demnach ein Modell in welchem TAM durch eine TGF-β abhängige 
Signalübertragung einen invasiven Tumorzellphänotyp via EMT ausbilden und 
gleichzeitig durch Signalübertragung von Chemokinen den Tumorzellen wachstums-
gerichtete Stimuli bieten. 
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Ein wichtiger Aspekt dieser Studie war die Evaluation der klinischen Relevanz der 
TAM-induzierten Tumor-EMT im Verlauf einer Tumorerkrankung. Diese Relevanz 
wurde durch eine histopathologische Analyse von 491 Tumorproben von nicht 
kleinzelligen Lungenkarzinomen („non-small cell lung cancer“, NSCLC) bestätigt, 
wobei eine signifikante Korrelation zwischen intra-tumoraler Makrophagendichte, 
mesenchymalem Tumorzell-Phänotyp und dem Entwicklungsgrad der Tumore 
gezeigt werden konnte. Diese klinische Relevanz der grundlegenden in vivo und in 
vitro Ergebnisse weist darauf hin, dass therapeutische Ansätze gegen TAM den 
Krankheitsverlauf von EMT-assoziierten Tumorformen möglicherweise verbessern 
könnten. 
Insgesamt kann durch die Resultate aus meiner Doktorarbeit eine neuartige 
Dimension im komplexen Zusammenspiel von Tumorzellen und der Tumor-
mikroumgebung erkannt werden. 
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1. Summary 
Tumor progression depends on a number of rate-limiting steps that are highly 
influenced by the tumor microenvironment. To this end, tumor associated 
macrophages (TAMs) are regarded as key regulators of tumor progression. This is 
in part due to their involvement in the “angiogenic switch” and their functions in 
modulating tumor growth. Moreover, TAMs secrete a vast amount of chemokines 
through which they attract motile cancer cells. These events facilitate and 
orchestrate tumor cell invasion and dissemination, thus TAMs are generally 
believed to promote tumorigenesis and metastatic disease. However, their exact 
involvement in these processes and the mechanisms of action remain elusive. 
Our laboratory and others have previously studied the versatile roles of TAMs 
in tumor progression by performing pharmacologic depletion of TAMs in tumor 
bearing mice. These studies successfully linked TAM-depletion to reduced tumor 
growth and identified TAM-dependent tumor-angiogenesis as a major regulator 
hereof. In the presented work, I have used this bisphosphonate-liposome based 
technique to deplete TAMs in F9-teratocarcinoma tumors. I have combined this 
technique with gene expression analysis performed on the isolated F9-tumors and 
identified gene expression profiles revealing additional and novel implications for 
TAMs in tumor growth and progression.  
Data obtained from this comparative gene expression analysis revealed a 
correlation between TAM density and a gene expression profile characteristic of 
epithelial to mesenchymal transition (EMT). EMT is a well characterized 
mechanism through which epithelial tumor cells can acquire an invasive, 
mesenchymal phenotype, and it is therefore regarded to be a rate-limiting step in 
tumor invasion and progression. Thus, the correlation between TAM density and 
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EMT-associated gene expression suggested a role for TAMs in regulation of EMT-
associated tumor invasion. This was confirmed in cell cultures of murine F9- and 
mammary gland NMuMG-cells by using molecular and cell biological techniques. 
Importantly, TAM-derived TGF-β and consecutive activation of the β-catenin 
pathway was identified as a main inducer of tumor cell EMT.  
TAM-induced EMT led to increased invasion in response to macrophage-
derived chemokines, however invasion was abrogated upon neutralization of TGF-
β1. TGF-β1 alone did not prove to be a potent chemoattractant for the tested cell 
lines, thus the data suggests that TGF-β regulates tumor cell invasion by induction 
of a chemotactic phenotype, rather than providing chemoattracting signaling. The 
data demonstrate a direct involvement of TAMs in the intrinsic regulation of 
invasive properties in tumor cells.  
An important aspect of this study was to evaluate the clinical relevance of 
TAM-induced tumor EMT in disease progression. This was done by a histo-
pathologic analysis of 491 non-small cell lung cancer specimens, which revealed a 
significant correlation between intra-tumoral macrophage density, mesenchymal 
tumor cell phenotype and tumor grade. This underscores the clinical relevance of 
the murine data and suggests that therapeutic targeting of TAMs may improve 
management of cancers susceptible to stroma induced EMT-associated disease 
progression. 
Collectively, the data obtained during the course of my PhD unravel a novel 
dimension in the complex interplay between tumor cells and the tumor stroma and 
provide novel insight valuable for the development of therapies abrogating EMT-
associated disease progression. 
5
Introduction 
 
 
 
2 Introduction 
After several decades of rapid advances in the development of cancer 
therapies, the disease remains the second most frequent cause of death in the 
western world. Cancer is essentially a genetic disease, although lifestyle and 
environmental factors are known to contribute, and for two decades the major 
research topic has been the identification and characterization of genetic 
alterations causing neoplastic cell transformation (Murga and Fernandez-Capetillo, 
2007). This has opened a window of therapeutic opportunities, targeting and 
eradicating cells with compromised integrity. However, the success of these 
therapies has been limited, suggesting that an important aspect of tumor 
pathogenesis has remained unresolved.  
Significant achievements made during the last two decades have led to the 
concept of “hallmarks of cancer”. These hallmarks are generally defined as 
alterations in gene expression leading to self sufficiency in cell growth, insensitivity 
to growth inhibiting signaling, limitless replication potential, evasion of apoptosis, 
acquisition of invasive properties and neo-angiogenesis (Fig. 1), (Hanahan and 
Weinberg, 2000). However, neo-angiogenesis has been found to be tightly 
regulated by extrinsic factors hosted by the tumor microenvironment (Ingber and 
Folkman, 1989, Hartlapp et al. 2001, Lin et al. 2006, Joyce and Pollard, 2009). 
The notion that the tumor microenvironment can be rate-limiting for tumor 
progression was first proposed by Stephen Paget in his “seed and soil” theory 
from 1889 (Ribatti et al. 2006). Paget postulated that a metastatic tumor is 
established only when the tumor cells and the host environment are compatible. A 
century later, experimental implantation of murine cancer cells in non-tumorigenic 
host environments confirmed that the malignant potential of neoplastic cells highly 
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depends on the nature of the host tissue (Mintz et al. 1975, Dolberg and Bissel, 
1984).  
Although these studies manifested the importance of the microenvironment in 
tumorigenesis, it is only during the past 15 years that we have begun to 
understand the underlying molecular mechanisms. Intensive investigations of 
these mechanisms have revealed a highly complex pattern of signal transducing 
pathways tightly regulated by the tumor stroma. Of the signaling pathways 
identified to date, a significant number are associated with wound healing and 
inflammation, and this has revived another century old paradigm stating that 
tumors are never healing wounds (Dvorak, 1986, Coussens and Werb, 2002, 
Grivennikov et al. 2010). This has led Mantovani and co-workers to propose tumor 
inflammation as the seventh “hallmark of cancer”, thereby highlighting the 
importance of the host environment in disease progression and concurrently 
drawing attention to paradigms made more than a century ago (Fig. 1), (Colotta et 
al. 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic illustration of the seven hallmarks of cancer. Adapted from Colotta et al.  2009. 
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The recognition that tumor progression is influenced by the microenvironment 
opens a new window of therapeutic opportunities. However, the success of 
therapies targeting the tumor stroma highly depends on the identification and 
thorough examination of key regulators hosted in the microenvironment. The 
following sections review our current knowledge of the tumor promoting properties 
of the microenvironment, and special attention will be given to tumor associated 
macrophages. 
 
2.1. Hosting a tumor; the tumor microenvironment 
Solid tumors are complex organ-like structures comprised of tumor cells, 
stromal cells and extracellular matrix (ECM). Although transformed epithelial cells 
represent the only malignant cell type, the cellular composition of the 
microenvironment, and the adapted behavior of infiltrated stromal cells, contributes 
significantly to the malignant potential of a tumor (Tse and Kalluri, 2007, Joyce and 
Pollard, 2009). Tumor cells recruit a vast amount of leucocytes, such as 
neutrophils, natural killer cells (NKs), macrophages, dendritic cells and T-cells, as 
well as mast cells and fibroblasts through extensive chemokine signaling (Bellocq 
et al. 1998, Wyckoff et al. 2004, Cozar et al. 2005, Parsonage et al. 2005, Kalluri 
and Zeisberg, 2006, Green et al. 2009, Joyce and Pollard, 2009, Tazzyman et al. 
2009). Upon tumor infiltration, these cells initiate a pro-inflammatory response 
similar to that known from wound healing (Dvorak, 1986, Coussens and Werb, 
2002).  
A central regulator of this pro-inflammatory response is the transcription factor 
nuclear factor-κB (NFκB), which is activated e.g. by tumor necrosis factor-α (TNF-
α) and lipo-polyssaccharide (LPS) mediated Toll-like receptor signaling (Tak and 
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Firestein, 2001, Lu et al. 2006, Wu and Zhou, 2010). Under normal homeostatic 
conditions, NFκB is sequestered in part by the adherence junction complex, where 
it associates with E-cadherin and β-catenin, and to a greater extent by its 
molecular inhibitor IκB (Novak et al. 1991, Lu et al. 2006, Solonas et al. 2008). 
NFκB is activated upon e.g. TNF-α mediated phosphorylation and following 
degradation of IκB or by phosphorylation and following dissociation of the 
adherence junction complex. The active NFκB translocates to the nucleus to 
initiate transcription of target genes, which includes various pro-inflammatory 
cytokines, mitogens and self regulating genes (Lu et al. 2006, Wu and Zhou, 
2010). The acute pro-inflammatory response is the initiating event in wound 
healing. It is followed by the “proliferative phase”, which is characterized by 
recruitment and proliferation of endothelial cells and capillary support cells for 
angiogensis, and recruitment of proliferating epithelial cells necessary for 
successful re-epithelialization. The final step in wound healing is tissue 
remodeling, which is mainly facilitated by infiltrated myofibroblasts, which 
contribute to this process by extensive secretion of matrix proteins. Moreover, 
myofibroblasts physically close the wound by docking on opposite tissue 
boundaries and via cellular contractions bring the wound margins together 
(Grinnell, 2000, Coussens and Werb, 2002). Upon wound closing, the pro-
inflammatory cytokines are substituted by anti-inflammatory cytokines 
consequently inducing apoptosis in the redundant infiltrates and the inflammation 
resolves (Maiuri et al. 2004, Lu et al. 2006). However, whereas the wound healing 
process is self-limited in part due to the self regulating loop of NFκB, the pro-
inflammatory response in tumors often persists and becomes chronic (Coussens 
and Werb, 2002, Lu et al. 2006).  
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As mentioned, due to the similarities is cellular composition, signaling and 
biology, solid tumors are often referred to as “never healing wounds” (Fig.2), 
(Dvorak, 1986, Coussens and Werb, 2002) 
 
Fig. 2. Schematic illustration of wound healing and tumor growth. A. Non pathologic tissues 
are highly organized structures with epithelial cells resting on the basement membrane. Upon 
rupture, the wound is temporarily closed by platelets and fibrin cloths and leucocytes and 
myofibroblasts are recruited to the site where they incite an acute pro-inflammatory response to 
mediate angiogenesis and epithelialization to close the wound. B. Invasive carcinomas are highly 
unorganized. Epithelial cells lose attachment to neighboring cells and to the basement membrane 
as they become motile and  neo-angiogenesis is randomly induced where neoplastic cells interact 
with remodeled ECM, inflammatory cells or myofibroblasts. The high production of pro-
inflammatory cytokines by tumor cells and inflammatory cells stimulates chronic inflammation and 
the production of matrix proteins and proteinases which, besides ECM remodeling, permeabilize 
the tumor vasculature and make them accessible for migratory tumor cells, thereby facilitating 
tumor dissemination and metastasis. Adapted from Coussens and Werb, 2002. 
 
2.1.1 Cancer associated fibroblasts and the ECM 
Myofibroblasts are mesenchymal cells derived from bone marrow precursors 
and they are recruited to sites of inflammation or tumors by epithelial cell derived 
chemokine gradients (Parsonage et al. 2005, Kalluri and Zeisberg, 2006). 
Although traditionally regarded to be of mesenchymal stem cell origin, emerging 
evidence suggests that a large fraction of fibroblasts found in the tumor stroma, 
the cancer associated fibroblasts (CAFs), may originate from trans-differentiated 
A  B 
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epithelial tumor cells (see section 2.4), (Iwano M. et al. 2002, Kurose et al. 2002, 
Franci et al. 2006, Radisky et al. 2007, Tse and Kalluri, 2007).  
Trans-differentiation can occur as a consequence of epithelial to mesenchymal 
transition (EMT), a cellular mechanism through which e.g. tumor cells lose their 
epithelial traits and acquire mesenchymal properties (Thiery, 2002, Nawshad et al. 
2005, Polyak and Weinberg, 2009). EMT is crucial for embryogenesis and tissue 
repair, and although it is traditionally regarded to facilitate cell migration, it may in 
the case of wound healing, represent a mechanism to rapidly supply an injured 
tissue with fibroblasts to mediate the repair (Thiery, 2002, Thiery et al. 2009).  
CAFs main activity in tumors is, as in the case of wound healing, remodeling of 
the ECM. They contribute dual sided to this process as they secrete proteinases 
for matrix breakdown, and simultaneously deposit matrix proteins directly into the 
matrix (Rodemann and Müller, 1991, Kessenbrock et al. 2010). Due to chronic 
inflammation, the production of matrix proteins often exceeds the local 
requirements which can result in desmoplasia, ultimately leading to mechanical 
invasion of the surrounding tissue (Coussens and Werb, 2002, Kalluri and 
Zeisberg, 2006).  
The ECM comprises proteoglycans, collagens and fibronectin, which fill out 
the interstitial spaces and provide a site of anchorage for migrating cells 
(Kessenbrock et al. 2010). Moreover, it is rich on laminins which are the main 
components of the basement membrane (Kalluri and Zeisberg, 2006). Besides 
supporting the tumor with connective tissue, the ECM plays an important role in 
cell signaling. It sequesters large amounts of cytokines and growth factors which 
are activated upon proteolytic cleavage of the matrix. It thus allows rapid and local 
growth factor mediated activation of cellular processes creating a dynamic tumor 
microenvironment with an obvious growth advantage (Kessenbrock et al. 2010). 
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In addition to these rather indirect implications in tumor progression, CAFs 
also contribute directly to the “hallmarks of cancer” through cytokine and growth 
factor signaling. To this end, they stimulate tumor cell proliferation through 
secretion of soluble growth factors and mitogens and they contribute to tumor 
angiogenesis by vascular endothelial growth factor (VEGF) and stromal derived 
factor-1 (SDF-1/CXCL12) mediated recruitment and proliferation of endothelial 
cells (Hlatky et al. 1994, Orimo et al. 2005, Kalluri and Zeisberg, 2006, Studebaker 
et al. 2008, Erez et al. 2010). Both SDF-1 and VEGF are potent chemoattractants 
for leucocytes, and CAFs may thus contribute significantly to chronic tumor 
inflammation (Leek et al. 2000, Orimo et al. 2005, Parsonage et al. 2005). CAFs 
implication in sustained tumor inflammation is further substantiated by a recent 
report in which gene profiling identified constitutive activation of the pro-
inflammatory NF-κB pathway in CAFs. Thus, cancer associated fibroblasts play a 
significant and versatile role in tumor progression, and as a consequence they 
represent a strong therapeutic target (Kalluri and Zeisberg, 2006, Tse and Kalluri, 
2007, Erez et al. 2010) 
 
2.1.2 Tumor infiltrating leucocytes 
Tumor infiltrating leucocytes constitute approximately 50% of solid tumors and 
are thus the main component of the tumor stroma (Sica et al. 2008a). This 
observation has traditionally been interpreted as an immune response against the 
tumor, but tumor immunology studies performed over the past decade has 
revealed a common cancer related shift in the classical immune response in favor 
of tumor growth (DeNardo and Coussens, 2007, Sica et al. 2008a). 
The polarization of leucocytes is determining for whether the immune system 
mounts a anti-tumorigenic or pro-tumorigenic response. In both cases the initial 
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event is and acute pro-inflammatory immune response mounted by innate immune 
cells, mainly by secretory myeloid derived cells (see section 2.2), natural killer 
cells (NKs) and mast cells (DeNardo and Coussens, 2007, Sica et al. 2008a, 
Grivennikov et al. 2010). These pro-inflammatory cells directly eliminate 
pathogens through cytotoxic responses and phagocytosis. Moreover they secrete 
a variety of cytokines and chemokines to recruit additional leucocytes, mainly 
lymphocytes of the adaptive immune system (DeNardo and Coussens, 2007, 
Grivennikov et al. 2010). Professional antigen presenting cells (APCs), e.g. 
dendritic cells and macrophages, play a crucial role in mounting the adaptive 
immune response, as they take up foreign antigens and present them to T- and B-
cells in the sentinel lymph nodes (DeNardo and Coussens, 2007). Successfully 
primed lymphocytes, CD4+ Th-cells and their cytotoxic CD8+ counterparts, 
subsequently infiltrate the damaged tissue and mount a cytotoxic response to 
eradicate pathogens (Th1 response). After successful eradication, the cytokine 
profile in the microenvironment changes to stimulate an anti-inflammatory 
reponse, which recruits CD25+ regulatory T-cells (CD25+Tregs) to induce immune 
tolerance and resolve the inflammation, leading to tumor rejection (Erdman et al. 
2005, Porcheray et al. 2005, DeNardo and Coussens, 2007, Grivennikov et al. 
2010), (Fig. 3). 
However, when the anti-inflammatory response fails, the inflammation 
becomes chronic. Suppression of the anti-inflammatory response is promoted by 
tumor derived IL-4, IL-5, IL-6, IL-10 and IL-13, and as a consequence CD4+ T-cells 
fail to activate CD8+ T-cells, and thereby the tumor effectively evades a cytotoxic 
response. Moreover, activated B-cells in cooperation with dendritic cells, 
contribute to immune evasion by converting naïve Th-cells into CD4+CD25+Tregs 
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further stimulating immune tolerance (Th2 response), (DeNardo and Coussens, 
2007, Moore et al. 2010, Grivennikov et al. 2010).  
 
 
Fig.3. Schematic illustration of the two major inflammatory responses associated with 
cancer development. The left scenario represents the anti-tumor response, in which Th1 
CD4+/CD8+ T-cells mediate a cytotoxic response in conjunction with pro-inflammatory 
macrophages (M1), ultimately eradicating the tumor. The right scenario depicts the situation in 
most solid tumors, in which the cytotoxic Th2 CD4+/CD8+ T-cell response is suppressed by pro-
tumorigenic macrophages (M2), myeloid suppressor cells (SCs) and activated B-cells and 
regulatory T-cells (Treg),  ultimately promoting tumor growth. Adapted from DeNardo and Coussens, 
2007.    
 
The cytokine profile of the tumor microenvironment additionally alters the 
phenotypes and functions of many innate immune cells. To this end, constitutive 
transforming growth factor-β (TGF-β) signaling was recently shown to skew the 
neutrophil phenotype from pro-inflammatory and anti-tumorigenic (N1) to mediate 
chronic inflammation and becoming pro-tumorigenic (N2), (Fridlender et al. 2009). 
This alternative activation of neutrophils naturally changes their secretome, and 
rather than fighting the tumor, the N2 phenotype takes on pro-tumorigenic 
properties similar to those described for macrophages in the following sections 
14
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2.2.1-2.2.3. Moreover, the N2 neutrophils effectively suppress CD8+ T-cell 
maturation, and thus directly induce immune tolerance (Fridlender et al. 2009). 
 
2.2  Tumor associated macrophages 
Similar to the “neutrophil switch”, macrophages can alternate between pro-
inflammatory (M1) and pro-tumorigenic (M2) phenotypes depending on signaling 
from the local environment (Ting and Rodrigues, 1980, Gordon, 2003, Mantovani 
et al. 2004, Sica et al. 2008b, Fridlender et al. 2009, Pollard, 2009). Macrophages 
differentiate from circulating monocytes upon recruitment to – and infiltration of- 
epithelial tissues in response to colony stimulating factor-1 (CSF-1) signaling (Lin 
et al. 2001). Upon infiltration, they are further stimulated by the local 
microenvironment to assume either the M1 or M2 phenotype. The M1 phenotype 
is generally activated by microbial products (e.g. LPS), TNF-α and interferon-γ 
(IFN-γ). M1 macrophages are antigen presenting, phagocytozing and produce 
large amounts of the pro-inflammatory cytokines interleukin-12 (IL-12) and 
interleukin-23 (IL-23), as well as inducible nitric oxide synthase (iNOS) and 
reactive oxygen intermediates (ROIs) (Mantovani et al. 2008, Sica et al. 2008b). 
iNOS and ROIs are on one hand important for T-cell maturation and on another 
they generate a hostile microenvironment for “non self” such as intruding micro-
organisms and tumor cells (Mantovani et al. 2008). However, in response to TGF-
β, IL-4 - IL-6, IL-10 and IL13, macrophages polarize into a M2 phenotype (Sinha et 
al. 2005a, Sica et al. 2008b, DeNardo et al. 2009, Bierie and Moses, 2010). A 
central event in M2 polarization is activation of NFκB, which leads to increased 
secretion of pro-tumorigenic cytokines such as TNF-α, IL-6 and IL-10, which help 
sustain a chronic inflammatory response in both paracrine and autocrine manners 
(Lu et al. 2006, Hagemann et al. 2008, Sica et al. 2008b, Porta et al. 2009, 
15
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Pollard, 2009, Biswas and Lewis, 2010, Mancino and Lawrence, 2010). M2 
polarized macrophages display poor, or completely lack, antigen presentation, and 
therefore fail to prime CD4+ T-lymphocytes. Moreover, IL-4 and IL-13 induce 
macrophage production of arginase, thereby depleting the microenvironment of 
arginine. Arginine is crucial for the production of iNOS and ROIs and the high 
expression of arginase therefore inhibits differentiation and maturation of naïve T-
cells (Sinha et al. 2005b). Interestingly, CD4+ T-cells produce large amounts of IL-
4 and therefore represent an efficient paracrine feedback loop in which CD4+ T-
cells and M2 macrophages support the pro-tumorigenic phenotype (DeNardo et al. 
2009). Besides mediating immune surveillance, M2 macrophages, much alike 
other leucocytes and CAFs, are a major stromal source of pro-tumorigenic 
cytokines, growth factors, and a variety of proteinases (Hagemann et al. 2004, 
Hagemann et al. 2005, Lin et al. 2006, Sica et al. 2008b, Pollard, 2009, Gocheva 
et al. 2010, Kessenbrock et al. 2010). Interestingly, experimental inhibition of the 
Iκκ/NFκB pathway in M2 macrophages induced an M1 phenotype which correlated 
with increased tumoricidal activity and overall tumor regression. The change in 
immune response was in part due to increased recruitment of NK-cells and in part 
due to abolishment of macrophage mediated immune suppression (Hagemann et 
al. 2008). This study highlights the importance of the macrophage polarization in 
paracrine signaling and orchestration of immune surveillance. Moreover, it 
provides a proof of principle of how macrophage polarization can be targeted and 
altered therapeutically (Hagemann et al. 2008).  
The paradigm of the “macrophage switch” provides a compelling model for 
macrophage differentiation, however it solely deals with two extremes of a broad 
spectrum of mononuclear subtypes represented in the highly complex and 
heterogeneous tumor tissue. This spectrum includes bone marrow derived cells, 
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myeloid-derived suppressor cells (MSDC, Gr1+CD11b+), Tie2+ macrophages and 
M1/M2 macrophages which display partially distinct and partially overlapping 
features and functions (Fig. 4), (Mantovani et al. 2004, Venneri et al. 2007, Yang 
et al. 2008, Mosser and Edwards, 2008, Martilla-Ichihara et al. 2009, Pollard, 
2009). Due to the well documented heterogeneity of myeloid infiltrates in solid 
tumors some flexibility is being added to the  “M1/M2 macrophage dogma” to 
generate a classification system in which macrophages are part of a continuum of 
different phenotypes infiltrating the establishing and growing tumor (Pollard, 2009). 
In this text I will make use of this flexibility and consequently refer to this group of 
myeloid derived subtypes with monocyte/macrophage properties as tumor 
associated macrophages  (TAMs). 
 
Fig. 4. A schematic illustration of the mononuclear phagocytic cell lineage and the control of 
macrophage differentiation by growth factors. Circulating monocytes migrate into tissues and 
differentiate into macrophages of various sub-phenotypes depending on the combination of 
cytokines present in the local microenvironment. LY6Chigh monocytes preferentially differentiate into 
dendritic cells, whereas LY6Clow and TEM+ monocytes differentiate into macrophages displaying 
various functions ranging from immunity and tissue repair to neo-angiogenesis. Adapted from 
Pollard, 2009. 
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2.2.1     TAMs regulate the angiogenic switch 
Tumor growth often exceeds vascular proliferation and as a consequence the 
tumor develops hypoxic regions. Besides low oxygen tension, hypoxia is 
associated with low levels of glucose, increased levels of lactate and low pH 
(Carmeliet and Jain, 2000, Pollard, 2009). These conditions activate the hypoxia 
inducible factor-1 (HIF-1) pathway resulting in tumor cell differentiation- and 
proliferation stop and increased secretion of pro-angiogenic factors such as 
VEGFs (Forsythe et al. 1996, Maxwell et al. 1997).  
VEGFs are endothelial cell mitogens that regulate angiogenesis both through 
recruitment of endothelial cells and stimulation of their proliferation (Maxwell et al. 
1997, Du et al. 2008). Whereas healthy vessels sprout from established 
vasculature, which is structurally supported by capillary supporter cells or 
pericytes, tumor-vessels are characterized by lack of pericyte association, which 
results in leaky and tortuous vessels (Carmeliet and Jain, 2000, Greenberg et al. 
2008).  
VEGFs are also potent chemoattractants for TAMs (Leek et al. 2000). Tissue 
histology of various tumor types has demonstrated that TAMs are recruited to- and 
aggregate in hotspots- located within avascular tumor regions (Leek et al. 2000, 
Lewis et al. 2000). Although tumor cells can induce neo-angiogenesis by secretion 
of VEGF, a major contribution of VEGFs originates from TAMs. This has been 
shown in various murine tumor models where TAM infiltration was abrogated 
either by silencing of the Csf-1 gene (Csfop/op), or by pharmacologic depletion, with 
the result of reduced tumor burden and significant decrease in angiogenesis (Lin 
et al. 2006, Zeisberger et al. 2006).  
Besides VEGF signaling, TAMs contribute to tumor angiogenesis by secreting 
MMPs and cathepsins involved in ECM remodeling, thereby making way for 
18
Introduction 
 
 
 
sprouting vessels (Hagemann et al. 2004, Lin et al. 2006, Gocheva et al. 2010). 
Thusm TAMs are considered to be key regulators of the “angiogenic switch” during 
tumor progression (Lin et al. 2006).  
 
2.2.2     Preparing the metastatic niche 
Genetic (Csf1op/op) or chemical (bisphosphonate liposome mediated) ablation 
of TAM infiltration in spontaneous and orthotopic murine models have also proven 
to be sufficient to abrogate metastasis formation. These observations assign a 
central role for TAMs in the metastatic process (Wyckoff et al. 2004, Yang et al.  
2008, Qian et al. 2009).  
Metastasis depends on a number of rate-limiting steps of which tumor cell 
intravasation, extravasation, colonization and outgrowth are the most significant. 
Invasive tumor cells intravasate into the blood stream mainly through the leaky 
tumor-vasculature. Once in the circulation system, tumor cells propagate to distant 
sites where they extravasate into new host tissues to form metastatic colonies 
(Joyce and Pollard, 2009).  
The tissue preference of metastasizing cells is highly cancer type specific (Bos 
et al. 2009, Nguyen et al. 2009, Zhang et al. 2009). Gene expression analyses of 
cells isolated from breast cancer patients with brain and lung metastasis have 
revealed distinct signatures of primary and metastatic cancer cells, as well as 
between lung and brain metastases (Bos et al. 2009). For example, cyclo-
oxogenase 2 (COX-2) and heparin binding EGF was highly expressed in tumor 
cells extravasating into lung and brain, but not in cells extravasating into bones 
and lever. Moreover, tumor cells extravasating to the brain showed high 
expression of the α2.6-sialyltransferase ST6GALNAC5, suggesting that surface 
sialylation can be determining for whether disseminating breast cancer cells 
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extravasate into the brain or to e.g. lungs (Bos et al. 2009). Moreover, cell type 
specific activation of pathways signaling survival and proliferation upon 
extravasation was identified and whereas breast cancer engraftment in bone was 
shown to depend on activation of the non-receptor tyrosine kinase Src, bone 
engraftment of lung adenocarcinomas was mediated partially by activation of the 
Wnt-pathway (Nguyen et al. 2009, Zhang et al. 2009).  
Metastatic gene expression signatures and activation of specific signaling 
pathways are important for tumor cell survival during circulation and tissue 
extravasation, however the host environment is crucial for colonization and 
metastatic outgrowth. Extravasating cells experience oxidative stress and to 
counteract this they recruit CD11b+VEGFR+ TAMs (Kaplan et al. 2005, Kaplan et 
al. 2007, Erler et al. 2009). Through extensive paracrine signaling, infiltrated TAMs 
induce angiogenesis, suppress cytotoxic immune responses, and stimulate tumor 
cell growth and proliferation. The colonization by metastatic tumor cells in foreign 
tissue therefore largely depends on the establishment of such TAM-mediated 
metastatic niches. The observation that tumor metastasis is abrogated upon 
genetic ablation or pharmacologic depletion of TAMs in murine models highlights 
the importance of myeloid recruitment, paracrine signaling and the metastatic 
niche in disease progression.  
 
2.2.3      Orchestrating tumor invasion 
The metastatic niche theory deals with events occurring during tumor cell 
circulation, extravasation and colony outgrowth, but not with the initiating event; 
tumor cell intravasation. The tumor vasculature plays a central role in this process 
as its leaky nature provides an obvious escape path for invasive tumor cells. The 
blood stream not only provides an escape path for disseminating tumor cells but 
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also an entry point for circulating non-malignant stroma cells. The tumor derived 
cytokines IL-4, RANTES and CCL2 stimulate an autocrine TNF-α loop in infiltrating 
TAMs resulting in an increased secretion of MMPs and cathepsins. These 
proteases further contribute to tumor cell intravasation as they through enzymatic 
digestion perforate the basement membrane and the endothelial barrier 
(Hagemann et al. 2004, Gocheva et al. 2006, Gocheva et al. 2010).  
Local tumor expansion likewise depends on proteolytic digestion of the ECM. 
Moreover, tumor cells have to migrate to- and proliferate within- the invasive front. 
This process is orchestrated via reciprocal tumor cell-TAM relay loops of CSF-
1/EGF, CSF-1/ SDF-1 and via the CCL5/RANTES axis (Wyckoff et al. 2004, 
Karnoub et al. 2007, Green et al. 2009, Joyce and Pollard, 2009, Patsialou et al. 
2009, Qian et al. 2009). In this sense, proteolytic degradation of the ECM mines 
the path, while TAM-derived chemokines lead the way for migratory tumor cells. 
The paracrine signaling network between tumor cells and TAMs thus provides 
important extrinsic regulation of tumor invasion and dissemination (Fig. 5).  
 
Fig. 5. Schematic illustration of the tumor promoting activities of inflammatory and bone 
marrow derived cells, including onset of the angiogenic switch (lymph and hem), promotion of 
tumor cell invasion and preparation of the metastatic niche. Adapted from Rüegg C. 2006. 
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2.3    Becoming motile; intrinsic regulation of tumor cell invasion 
A crucial step in tumor invasion is a phenotypic transition through which 
adherent epithelial cells acquire migratory properties. Several distinct pathways 
can mediate such trans-differentiation but common for them is that they induce 
changes in the expression of adherence molecules, reorganization of the 
cytoskeleton and formation of proteolytic membrane protrusions required for 
invasion of the surrounding environment as well as for chemotaxis (Friedl, 2004, 
Kedrin et al. 2007, Yilmatz and Christofori, 2009). Although the dynamics of cell 
migration have been widely studied in the context of development and pathology, 
the means of regulation in a tumor context remain elusive. The following sections 
review the key steps in the different cellular pathways employed in the process of 
cell migration. 
 
2.3.1 The amoeboid approach; generation of Invadopodia 
The term invadopodia generally refers to membrane protrusions generated by 
transformed cells in contrast to podosomes, which predominantly refers to 
protrusions formed in migrating leucocytes (Gimona et al. 2008, Yilmatz and 
Christofori, 2009). A key step in invadopodia formation is reorganization of the 
actin cytoskeleton. This step is regulated by a complex signaling network involving 
growth factor receptor signaling (e.g. EGF, HGF, TGF-β), integrin β1 and β3 
signaling and non receptor tyrosine kinase signaling, mainly Src. Activation of 
these pathways initially leads to destabilization of the cytoskeleton either through 
partial or complete disruption of the membranous actin complexes (Kedrin et al. 
2007, Yamaguchi and Condeelis, 2006, Yilmatz and Christofori, 2009). 
Subsequent activation of e.g. the phosphoinositide-3-kinase (PI3K) and the 
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phospholipase Cγ (PLC) pathways leads to downstream activation of the small 
GTPases RhoA, Rac and Cdc42 (Kedrin et al. 2007). Rac is shuffled to the 
protrusion, also termed the leading edge, where it activates the actin related 
protein 2/3 complex (Arp2/3) to induce actin nucleation (Kedrin et al. 2007, Wang 
et al. 2010). The newly cross-linked actin filaments provide mechanical support for 
the protrusion, which is necessary to withstand the mechanical shear force 
provided by the invaded ECM. For complete cell movement, actin filaments 
located in the trailing edge have to retract, a process regulated mainly by RhoA 
and Cdc42 (Kedrin et al. 2007). 
During the formation of new protrusions, integrin receptors are shuffled to the 
surface of the tip. Here they sense chemokine signaling from the local 
microenvironment and when stimulated accordingly they establish temporary 
contact to the underlying ECM (Fig. 6), (Friedl, 2004).  
 
 
 
Fig. 6. Schematic illustration of cell migration 
mediated by protrusions.  
1) protrusions are formed in the leading edge and 2) 
integrins are shuffled to the surface of the tip to 
mediate adhesion to the ECM while the trailing edge 
detaches and unpolymerized actin is shuffled to the 
leading edge. 3) The trailing edge is moved forward 
due to myosin-mediated contractility, and cell has 
successfully moved ahead. Adapted from: 
http://www.biolsci.org/getimage.php  
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A recent report investigating Rac activation in drosophila border cells have 
identified an interdependency between localization of Rac to the protrusions and 
activation of tyrosine kinase receptors, such as EGFR. This finding may suggest 
that whereas Rac is important for actin nucleation in the forming invadopodia, 
activation of tyrosine kinase receptors may be important for chemotaxis in a  
similar manner as integrin β1 and β3 (Wang et al. 2010).  
A distinct feature of the invadopodia is their ability to degrade the ECM. 
Membrane type MMPs (Mt-MMPs) and serine protease uro-kinase plasminogen 
activator (uPA) and its receptor (uPAR) are recruited to the leading edge of the 
cells from where they actively participate in degradation of the surrounding tissue 
(Friedl, 2004, Yilmatz and Christofori, 2009).   
The ultimate inducing event leading to the formation of invadopodia remain 
elusive, however it is well acknowledged that membrane protrusions can arise 
spontaneously when tumor cells are grown on an appropriate substrate such as 
collagens naturally found in the ECM. This could suggest the involvement of a 
positive feed forward mechanism linking ECM remodeling and activation of 
integrins to the initial formation of invadopodia (Gimona et al. 2008).  
 
2.3.2 Following the lead; cluster invasion 
Epithelial cells can either migrate as single cells or in clusters. Cluster invasion 
is mainly known from embryogenesis and wound healing, but the phenomenon 
has also been reported for various cancers during tissue invasion and 
intravasation into the circulation system (Friedl and Gilmour, 2009).  
Cluster invasion requires partial cell-cell cohesion, collective cell polarization 
and intercellular coordination of cytoskeletal remodeling activity. The protrusions 
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are formed mainly in the leading cells, whereas cells located in the rear end 
display a predominant retractile phenotype. Cells located between the front and 
the rear end can adapt completely, partially or not at all, depending on their 
position. The centre cells thus vary from displaying temporary or partial protrusion 
formation, localized enzymatic activity or an adherent epithelial phenotype (Fig. 7). 
Cluster invasion thus provides a functional mechanism for invasion by cells that by 
nature are immotile or display poor migratory properties (Friedl and Gilmour, 
2009). 
 
 
Fig. 7. Schematic illustration of collective invasion in the ECM by detached cancer cells which are 
moving as a small cluster. The leader cells (blue cells to the right) display, as the only cells in the 
cluster, taxis sensing and proteolytic protrusions. Other cells in the cluster are directly or indirectly 
attached to the leader cells through adherence junctions, and only the cells lining the cluster 
display proteinase activity and partial membrane protrusion. Adapted from Friedl and Gilmour, 
2009. 
 
The mechanisms controlling and defining the development of cluster invasion 
are poorly understood (Friedl and Gilmour, 2009). However, recent studies have 
provided some useful insights e.g. by. identifying Rac as an important intrinsic 
mediator of cluster invasion (Wang et al. 2010). Rac was shown to be differentially 
expressed among cells in the cluster, and polarized expression in leading cells 
was sufficient to promote invasion by the entire cluster. As the clustered cells are 
tied together by epithelial adherence junction, physical disruption hereof may be a 
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determining factor. The epithelial adherence protein E-cadherin is a known 
substrate for MMPs and Cathepsins, suggesting that proteinase mediated 
disruption of adherence junctions, e.g. as a consequence of tissue remodeling 
may play a role (Gocheva et al. 2006, Orlichenko and Radisky, 2008). Extrinsic 
processing of E-cadherin, in combination with the differential genomic integrity 
characteristic for mammalian tumors, may determine which cells in a cluster 
activate Rac and become invasive, and which passively follow the lead ) Friedl 
and Gilmour, 2009, Gocheva et al. 2006, Orlichenko and Radisky, 2008).   
 
2.3.3 Going solo; single cell invasion 
The alternative to cluster invasion is single cell invasion. Intra-vital imaging of 
murine tumors recently revealed that rapid and transient exposure of tumor cells to 
TGF-β1 is sufficient to induce a switch from clustered to single cell invasion 
(Giampieri et al. 2009). Moreover, using this technique it was demonstrated that 
clustered invasion solely homes to the lymphatic system, whereas single cells 
intravasates into both lymphatics and the blood stream, the latter resulting in 
metastasis (Giampieri et al. 2009, Giampieri et al. 2010). 
Single cells can employ either an amoeboid (Fig. 6) or mesenchymal (see 
section 2.4 and Fig. 8) strategy upon invasion. The two strategies are distinct 
although they share some common features like complete loss of epithelial 
adherence junctions, stress fiber generation and morphological changes (Friedl, 
2004, Matise et al. 2009). Whereas classical amoeboid migration (via podosomes) 
is associated mainly with leucocyte trafficking, mesenchymal cell migration is the 
predominant mean of single cell migration in epithelial cancers (Yilmatz and 
Christofori, 2009, Matise et al. 2009). Interestingly, TGF-β has previously been 
shown to induce mesenchymal trans-differentiation in epithelial cancer cells 
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through activation of the RhoA pathway, suggesting that the recently identified 
implication for TGF-β in single cell invasion may be related to its role in epithelial 
to mesenchymal transition (Bhowmick et al. 2001, Matise et al. 2009) 
  
2.4    Epithelial to mesenchymal transition 
Epithelial cells can acquire mesenchymal features by undergoing EMT (Thiery, 
2002, Nawshad et al. 2005, Thiery et al. 2009, Yang and Weinberg, 2008). 
Although initially characterized as a crucial mechanism for embryogenesis, it is 
gaining acknowledgement for its potential involvement in promoting tumor invasion 
and metastasis (Thiery et al. 2009, Yang and Weinberg, 2008). This is in part 
based on research conducted in a number of cancer cell lines with the ability to 
undergo such trans-differentiation in vitro, and in part on a number of clinical 
studies successfully correlating EMT marker expression in tumor samples with 
poor disease outcome (Bakin et al. 2000, Lu et al. 2003, Gal et al. 2008, 
Soltermann et al. 2008, Thiery et al. 2009, Yang and Weinberg, 2008).  
In brief, cancer cells can trans-differentiate in response to intrinsic events, e.g. 
genetic mutations, or extrinsic signaling e.g. from the tumor stroma (see section 
2.4.4), (Gazit et al. 1999, Bakin et al. 2000, Bhowmick et al. 2001, Lu et al. 2003, 
Thiery and Sleeman, 2006, Gal et al. 2008, Thiery et al. 2009). As illustrated in fig. 
8, the highly organized structure that characterizes epithelial tissues is lost during 
EMT (dysplasia), as the cells reorganize their cytoskeleton, change morphology 
and become fibroblast-like (carcinoma in situ). Moreover, the cells up-regulate the 
production of proteases and become invasive (invasive carcinoma), (Thiery, 2002, 
Yilmatz and Christofori, 2009). Via extensive proteolysis, the trans-differentiated 
cancer cells break through the basement membrane and intravasate into the 
circulation system where they travel up against chemokine gradients provided by 
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pre-metastatic and metastatic niches. Upon arrival to a new host tissue, the cancer 
cells extravasate into the metastatic niche where they potentially undergo the 
reverse mechanisms, mesenchymal to epithelial transition (MET). MET represents 
a mechanism through which trans-differentiated cancer cells can regain their 
epithelial phenotype, colonize and establish micro metastasis (Fig. 8), (Thiery, 
2002, Hugo et al. 2007, Thiery et al. 2009).    
 
Fig. 8. Schematic illustration of the cellular changes of epithelial tumor cells undergoing 
EMT. At the state of complete trans-differentiation, the cells are highly invasive and can intravasate 
into the circulation system. Upon extravasation the cells undergo MET to regain epithelial traits. 
Adapted from Thiery, 2002. 
 
EMT may also play a crucial role during local tumor invasion. Instead of 
intravasation, the trans-differentiated cells may use their proteolytic activity to 
degrade the ECM. Chemotaxis allows them to migrate towards the invasive front 
of the tumor, constantly being on the edge to the surrounding tissue (Thiery, 2002, 
Thiery et al. 2009).    
Besides tumor cell invasion, EMT is thought to confer a drug resistance 
potential as well as stem cell like properties (Mani et al. 2008, Thiery et al. 2009, 
Polyak and Weinberg 2009, Santisteban et al. 2009, Reiman et  al. 2010). 
Moreover, EMT has been linked to increased production of reactive oxygen 
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species (ROS), consequently facilitating oxidative DNA damage and genomic 
instability (Radisky et al. 2005, Inumaru et al. 2009, Zhou et al. 2009). It has 
therefore been speculated that abrogation of tumor cell EMT could be of value for 
successful future therapies (Mani et al. 2008, Polyak and Weinberg, 2009, Thiery 
et al. 2009). 
 
2.4.1 Molecular hallmarks of EMT 
A key step in EMT is loss of E-cadherin. Whereas the extracellular domain of 
this transmembrane glycoprotein mediates homophillic adherence junctions with 
neighboring cells, the intracellular domain forms complexes with the transcriptional 
co-activator β-catenin and the cytoskeleton linker protein α-catenin (Nawshad et 
al. 2005). Upon loss of E-cadherin the complex dissociates, the proteins are 
released, the cytoskeleton rearranges and β-catenin can associate with 
transcription factors of the T-cell factor/lymphoid enhancer factor (Tcf/Lef) families 
and induce transcription of, among other, mesenchymal hallmark genes such as 
N-cadherin, the intermediate filament vimentin and the ECM component 
fibronectin (Korinek et al.1997, van de Wettering et al. 2002, Schmidt-Ott et al. 
2007). E-cadherin can be transcriptionally repressed by members of the SNAI 
(e.g. snail and slug), bHLH (e.g. twist) and ZEB (zeb1/2) families, which meditate 
suppression by directly binding to the E-box sequence in the E-cadherin promoter 
(Cano et al. 2000, Chua et  al. 2007, Vesuna et al. 2008).  
Loss of E-cadherin often correlates with expression of N-cadherin, a 
phenomenon referred to as the “ cadherin switch” which, along with up-regulation 
of snail and twist, is regarded molecular signatures of EMT (Maeda et al. 2004, 
Nawshad et al. 2005). 
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2.4.2 Signaling EMT 
EMT can be regulated through a number of intrinsic signaling pathways, 
including but not limited to tyrosine kinase receptor signaling, e.g. EGFR, Wnt/β-
catenin, Notch, integrin mediated and TGF-β receptor signaling (Gazit et al. 1999, 
Bakin et al. 2000, Bhowmick et al. 2001, Lu et al. 2003, Thiery and Sleeman, 
2006, Gal et al. 2008, Thiery et al. 2009). The signaling cascades required to 
induce EMT are highly context dependent and although activation of one pathway 
can be sufficient to incite trans-differentiation, multiple pathways are often found to 
signal in conjunction to mediate a sustainable response (Nawshad et al. 2005, 
Thiery and Sleeman, 2006, Lo et al. 2007, Dissanayake et al. 2007, Labbé et al. 
2007, Uttamsingh et al. 2008, Vincent et al. 2009).  
In a simplified view, the many EMT regulating pathways converges at the 
transcriptional level. Essentially, activation of the surface receptors results in up-
regulation of snail and/or twist, which mediate suppression of E-cadherin. As a 
consequence the adherence complexes dissociates and the transcription factors 
NFκB and β-catenin, which are normally sequestered in the complex, are released 
(Solonas et al. 2008) . Moreover, EMT signaling can inhibit protein degradation by 
mediating phosphorylation, and thus inactivation, of glycogen synthase kinase-3-β 
(GSK3β). Consequently NFκB and β-catenin are stabilized and can translocate to 
the nucleus to initiate the EMT transcription program (Fig. 9), (Thiery and 
Sleeman, 2006).  
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Fig. 9. Schematic illustration of selected molecular networks and their crosstalk, involved in 
regulation of EMT. Receptor tyrosine kinases (RTKs) are known to induce EMT in several 
epithelial cancer cell lines, however its signaling highly depends on co-activation of integrin 
receptors. Together they activate Rac, which induces cytoskeleton remodeling as described in 
section 2.3.1. RTKs furthermore signal EMT through sequential activation of MAPK and snail 
mediated repression of E-cadherin and consequential induces onset of the EMT transcription 
program. Canonical Wnt signaling mediates stabilization of snail through direct inhibition of GSK3β. 
Snail represses E-cadherin, which in turn releases β-catenin and NFκB. Upon translocation to the 
nucleus they initiate the EMT transcription program. TGF-β signaling has been extensively studied 
for its involvement in EMT in vitro and in vivo. The canonical pathway signals through SMAD, which 
induces snail mediated E-cadherin repression. The non-canonical signaling path for TGF-β goes 
through PI3K/Akt and RhoA. PI3K/Akt activation induces a NFκB response and twist mediated E-
cadherin repression, whereas signaling through RhoA mainly induces cytoskeleton remodeling as 
described in section 2.3.1. Notch signaling has gained recent acknowledgement for its potential to 
induce EMT, however the pathways through which it regulates EMT are still under investigation. 
MMP3 induces EMT through activation of Rac1b, which further induces the production of ROS 
consequentially stabilizing snail and repressing E-cadherin. Adapted from Thiery and Sleeman, 
2006.  
 
EMT can also be induced as a consequence of inherited or acquired genetic 
mutations. Naturally, mutations in the cytokine receptors can activate EMT 
signaling, but also downstream mutations can result in constitutive activation of the 
EMT transcription program. An example hereof is colon cancer, which 
predominantly is caused by loss-of-function mutations in the tumor suppressor 
adenomatosis polyposis coli (APC) gene or gain-of-function mutations in β-catenin 
(Korinek et al. 1997, Morin et al. 1997, Brabletz et al. 2001). Moreover, a recent 
study identified a correlation between common K-Ras mutations and EMT 
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signaling pathways, suggesting that K-Ras mutations may enhance EMT inducing 
signaling (Singh et al. 2009). The importances of such synergies are further 
supported by the observation that Ras-transformed hepatocytes, kidney (MDCK) 
and mammary epithelial (EpH4) cells, to mention a few, only undergo complete 
EMT upon co-activation of the TGF-β pathway (Oft et al. 1996, Janda et al. 2002, 
Tse and Kaluri, 2007).  
 
2.4.3 TGF-β; Dr. Jekyll and Mr. Hyde 
TGF-β was originally identified as a tumor suppressor gene and it is a potent 
controller of cell proliferation and apoptosis (Massague, 1998). The canonical 
signaling pathway involves SMAD activation, which upon nuclear translocation 
induces transcription of targets genes. However, for example as a consequence of 
Ras-mutations or tyrosine kinase receptor activation, TGF-β can switch to signal 
through non-canonical pathways, such as the PI3K/AKT and/or the RhoA 
pathways and rather than suppressing tumor growth, TGF-β induces single cell 
invasion (Fig. 9), (Bakin et al. 2000, Bhowmick et al. 2001, Akhurst and Derynck, 
2001, Nawshad et al. 2005, Thiery and Sleeman, 2006, Gal et al. 2008, Giampieri 
et al. 2009, Matise et al. 2009).  
TGF-β has been extensively investigated for its role in EMT and on this note, it 
was not surprising that TGF-β was identified as a key factor inducing single cell 
migration instead of clustered migration (Giampieri et al. 2009, Giampieri et al. 
2010). However, the notion that TGF-β induced single cell migration ultimately 
leads to metastasis at distant sites may highlight the detrimental consequences of 
tumor cell EMT. Although the significance of EMT in tumor cell invasion is 
generally accepted, it is important to note that it mainly is based on in vitro studies, 
and that the in vivo evidence is limited mainly to histo-pathologic correlation 
32
Introduction 
 
 
 
studies of tumor samples from patients (Bakin et al. 2000, Bhowmick et al. 2001, 
Soltermann et al. 2008, Thiery et al. 2009, Vincent et al. 2009). This is in part due 
to the transient nature of EMT, which makes it difficult to detect trans-differentiated 
cells with existing visualization techniques. But it is also due to the fact that 
epithelial cells that have undergone complete EMT, morphologically and 
phenotypically resemble myofibroblasts, which makes it difficult to distinguish 
between the fibroblast-like cells of mesenchymal and epithelial origin (see section 
2.1.1), (Franci et al. 2006, Radisky et al. 2007, Kalluri and Zeisberg, 2006, Tse 
and Kalluri, 2007). As a  consequence we know a lot about the intrinsic regulation 
of tumor cell EMT, but in reality we know very little about its extrinsic regulation in 
a tumor context in vivo.  
 
2.4.4 Stromal regulation of EMT 
Histo-pathology analyses of human tumor specimens have revealed a rather 
large population of mesenchymal-like tumor cells in the invasive front where they 
closely associate with components of the tumor stroma. This observation has been 
interpreted as a sign of extensive tumor-stroma communication inciting the 
phenotypic conversion of epithelial tumor cells to invasive mesenchymal cells 
(Brabletz et al. 2001, Franci et al. 2006, Sheehan et al. 2008). The tumor 
microenvironment is a constant source of growth factors and cytokines such as 
TGF-β, EGF and Wnt to mention a few, that potentially can signal EMT through 
canonical receptor activation (Gazit  et al. 1999, Bakin et al. 2000, Bhowmick et al. 
2001, Lu et al.  2003, Gal et al. 2008, Vincent et al. 2009). To this end, it has been 
suggested that Th2 polarized CD4+/CD8+ T-lymphocytes, possibly through 
paracrine TGF-β signaling, can contribute to an EMT inducing tumor 
microenvironment and enhance invasion in vivo as well as promote disease 
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recurrence (Santisteban et al. 2009, Reiman et  al. 2010). Disease relapse is 
generally associated with cancer stem cells, and to this end several reports have 
identified extensive similarities between trans-differentiated epithelial cells and 
cancer stem cells (Mani et al. 2008, Polyak and Weinberg, 2009, Santisteban et al. 
2009, Reiman et al. 2010). Depletion of CD8+ T-cells in a murine mammary tumor 
model completely abolished EMT and prevented relapse, underscoring the 
importance of CD8+ T-cells both in the regulation of tumor EMT and stem-like cell 
induced disease recurrence. However, the mechanisms of action are poorly 
understood, and although Th2 polarized T-cells is a strong source of TGF-β, its 
involvement in T-cell regulated EMT remains speculative (Reiman et al. 2010).   
Stroma-derived proteinases, particularly MMP3, MMP9 and Cathepsin B, can 
cleave E-cadherin and induce its internalization via endosomes, which alone can 
be sufficient to induce an EMT response (Fig. 9), (Radisky et al. 2005, Gocheva et 
al. 2006, Orlichenko and Radisky, 2008, Gocheva et al. 2010). Moreover, MMP-3 
has been shown to regulate alternative splicing of Rac1, generating Rac1b, which 
in turn stimulates the production of ROS and induce oxidative DNA damage, 
thereby facilitating genomic instability. This pioneer study was the first to link the 
molecular pathways of EMT to genomic instability (Radisky et al. 2005). Recent 
studies have further confirmed this link, however it has become evident that 
whereas ROS production is sufficient to induce a temporary EMT response 
characterized by internalization of adherence molecules from the plasma 
membrane, it is not enough to induce a sustainable EMT phenotype (Inumaru et 
al. 2009, Zhou et al. 2009). Interestingly, the sustainability of ROS induced EMT 
seems to depend on additional stimuli from e.g. TGF-β and constitutive activation 
of the pro-inflammatory NFκB-pathway (Tobar et al. 2010). Collectively, these 
reports give way for the possibility that tumor cell EMT may be regulated by tumor 
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inflammation, a possibility that needs further investigation but hold interesting and 
promising potential in terms of developing novel adjuvant therapies. The studies 
emphasize the exiting need to further explore this complex tumor-stroma crosstalk 
to identify the stromal sources of factors regulating EMT associated tumor 
progression. 
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3 Aim(s) of study 
As reviewed above, the tumor microenvironment plays crucial and versatile 
roles in tumor progression. Therapeutic targeting of the tumor stroma therefore 
holds great promises for improved cancer management. However, the success of 
such therapies highly depends on careful identification and characterization of the 
multiple players and molecular processes involved in the various steps of tumor 
progression.  
Our laboratory has previously developed a technique utilizing bisphosphonate-
liposomes to deplete TAMs in tumor bearing mice. This technique has been used 
with great success to investigate and characterize the many and versatile 
implications for TAMs in tumor promotion (Zeisberger et al. 2006, Yang et al. 
2008, Qian et al. 2009). Moreover, in conjunction with molecular as well as cell 
biological techniques, it has formed the basis for my PhD project, in which I have 
sought to identify novel implications for TAMs in tumor progression.  
Essentially the aims of this study can be condensed into three main points, 
where aim two and three are direct consequences of aim one, namely: 
 
1) To identify novel implications for TAMs in tumor progression 
2) To investigate the regulatory role of TAMs in tumor cell EMT  
3) To validate the clinical relevance of TAM regulated tumor EMT 
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4 Results 
The data presented in this section represents my PhD work (Dec. 2006 - Aug. 
2010). The experiments were mainly conducted at the Institute of Molecular 
Cancer Research, University of Zürich. The micro array experiments were 
performed in collaboration with the Functional Genomics Center Zürich and the 
analysis of the clinical data were done in collaboration with two pathologists, MD. 
Alex Soltermann and MD. Verena Tischler, Department of Surgical Pathology, 
University Hospital Zürich. All institutions are situated in Zürich, Switzerland. The 
supplementary material is enclosed in Appendix 1, the quality assessments of the 
mRNA used for the micro array experiment is shown in Appendix 2, and the title 
page of the manuscript and the abstract is enclosed as Appendix 3.   
 
4.1   
Macrophage depletion; proof of principle 
To identify novel roles for TAMs in tumor progression, gene expression 
patterns in F9-teratocarinoma tumors infiltrated by- or depleted of- macrophages 
were analyzed. The F9-teratocarcinoma model represents a good model for this 
study as the F9-cells are plastic cells that are sensitive to stimuli by certain 
cytokines in vitro (Krawetz and Kelly, 2008). Moreover, subcutaneously implanted 
F9-tumors are heavily infiltrated by TAMs and the model is thus susceptible to 
pharmacologic TAM depletion (Zeisberger et al. 2006).  
Macrophages were depleted in tumor bearing mice using a liposome based 
technique, previously established by our group (Zeisberger et al. 2006). In brief, 
the bisphosphonate compound clodronate is intracellularly incorporated into non-
hydrolysable analogues of adenosine triphosphates (ATPs), which ultimately leads 
the affected cells into apoptosis (Selander et al. 1996), (Fig. 10A). Clodronate has, 
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due to its negative charge, a high affinity to bone matrix, and it mainly accumulates 
in the bones when administered in its free form in vivo (Graham and Russell, 
2007). Accumulation in the bone matrix can be prevented by encapsulating 
clodronate in liposomes (clodrolip). Encapsulation furthermore increases the 
circulation time and allows the drug to be deposited in tissues and organs other 
than bone. Most importantly, liposomes are phagocytozed by macrophages, and 
thus the technique provide a tool for macrophage depletion in vivo (Zeisberger et 
al. 2006) 
  The cytotoxicity of clodrolip and empty control liposomes was assessed in a 
live cell viability assay using M2 polarized RAW 264.7 macrophages in vitro (Fig. 
10B), (Wang et al. 2007). Having confirmed the cytotoxic effects of clodrolip, and 
lack of toxicity of the empty control liposomes in vitro, the liposomes were applied 
in tumor bearing mice in vivo. F9-teratocarcinoma bearing SV129J1 mice were 
treated with empty liposomes (control) or with clodrolip every 3rd day (1 mg/20g 
body weight) for three weeks, isolated and subjected to preliminary micro array 
analyses (Fig. 10C). During the course of treatment the development of the tumors 
were followed by mean of size estimation (data not shown). At the end of the 
experiment, the mean tumor volume was significantly smaller in clodrolip treated 
tumors relative to control tumors (Fig. 10D).  
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Fig. 10. Assay design and generation of control and macrophage depleted F9-tumors. A. 
Schematic illustration of the basic principle of clodrolip mediated macrophage depletion. 
Clodronate is incorporated into non-hydrolysable ATPs. By encapsulating clodronate in liposomes, 
which are mainly taken up by phagocytozing cells, clodronate (clodrolip) is efficiently delivered to 
the macrophages. Upon phagocytosis of clodrolip, macrophages undergo apoptosis.  B. Live cell 
viability assay (24h) estimating the cytotoxicity of clodrolip and empty liposomes on M2 polarized 
RAW264.7 macrophages in vitro. C. Schematic illustration of the work flow implemented to identify 
novel roles for TAMs in tumor progression. F9-teratocarcinoma tumors were implanted on the 
flanks of SV1291J mice that  were treated  over the course of 3 weeks with either clodrolip or 
empty liposomes. After termination, the tumors were isolated and subjected to micro array analysis. 
D. Tumor size (mm3) distribution at the day of termination of the experiment, in control mice or 
clodrolip treated mice.  ** represents p < 0.005, unpaired t-test.   
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Clodrolip treated tumors were significantly smaller than control tumors by the 
end of the study (Fig. 10D). To assess if the reduction in tumor growth correlated 
with depletion of TAMs, a comparative gene expression analysis of 
monocyte/macrophage specific markers was performed. The microarray data 
revealed a marked decrease in expression of the macrophage specific markers 
CSFR-1 (~ 5,5 fold), CD68 antigen (~ 3 fold), mannose receptor c (~ 9 fold) and 
monocyte to macrophage differentiation factor (~ 2 fold) in clodrolip treated tumors 
relative to controls (Fig. 11A and Table 1). Quantitative real-time PCR (q-PCR) 
analysis confirmed a reduction in expression of CSFR-1 (~ 4 fold) and CD68 (~ 2 
fold) in clodrolip treated tumors relative to controls (Fig. 11B).  
Finally, macrophage depletion was confirmed by immunohistochemical 
analysis of the macrophage specific markers F4/80 and CD68 (Fig. 11C). Our 
group has previously demonstrated that TAM depletion reduces tumor growth as a 
consequence of reduced tumor-angiogenesis (Zeisberger et al. 2006). To this end, 
the micro array analysis confirmed a correlation between expression of 
macrophage specific markers and  expression of genes involved in angiogenesis. 
Whereas the endothelial cell specific receptor, endothelin receptor B and 
thrombospondin 1 were down regulated in clodrolip treated tumors  (~  3 fold,  and  
~ 5 fold, respectively), the anti-angiogenic procollagen 18 was up-regulated 
relative to control tumors (~ 2 fold), (Fig. 11D). Clodrolip-mediated reduction of 
angiogenesis was further confirmed by immunohistochemistry, analyzing the 
expression of the endothelial cell specific antigen, CD31 (data not shown). Thus, 
we concluded that clodrolip efficiently depleted TAMs in the F9-tumors and that 
depletion was sufficient to abrogate biological TAM regulated processes, such as 
angiogenesis, important for tumor growth. 
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Table 1: Relative expression of selected genes in F9-tumors in response to 
clodrolip mediated TAM depletion. 
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Fig. 11. Clodrolip mediated macrophage depletion in F9-teratocarcinomas. A. Relative fold gene 
expression (mRNA levels, micro array analysis), of the monocyte/macrophage specific markers CSFR-
1 (Csfr-1), CD68 (Cd68), mannose  receptor C (Mrc) and monocyte-macrophage differentiation marker 
(Mmd) in clodrolip treated vs. control F9-tumors; n=2, bars:±SEM. B. Relative fold gene expression 
(mRNA  levels,  q-PCR) of CSFR-1 and CD68 in clodrolip treated vs. control F9-tumors; n=6, 
bars:±SEM. C. Immunohistochemical analysis of F4/80+ (green) and CD68+ (red) density in control 
(upper panel) and clodrolip treated (lower panel) F9-tumors. Overlay shown in orange; scale bar=0.2 
mm. Nuclei were stained with DAPI (blue). D. Relative fold gene expression (mRNA levels, micro array 
analysis), of the angiogenic markers endothelin receptor b  (Erdnrb),  thrombospondin 1 (Thbd1) and  
procollagen 18 (Col18a1) in clodrolip treated vs. control F9-tumors; n=2, bars:±SEM.  
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4.2 
Identification of novel roles for TAMs in tumor progression; A link between 
TAM infiltration and epithelial cell migration 
Another important aspect of tumor growth is remodeling of the ECM and to this 
end, the gene expression analysis revealed a direct correlation between TAM 
depletion and reduced expression of selected proteases important for proteolytic 
degradation of the ECM (Fig. 12A and Table 1), (Kessenbrock et al. 2010). 
Besides reduced expression of matrix metalloproteinase 14 (~ 2 fold), cathepsin B 
and cathepsin H (~ 2 fold, and ~ 4.5 fold, respectively), the matrix protein 
fibronectin and the basal laminae component, laminin B were reduced ~ 2.5 fold 
and ~ 2 fold, respectively, in clodrolip treated tumors relative to controls (Fig. 12A). 
As TAMs are known to be a major source of MMPs and cathepsins in the tumor 
microenvironment, the relative reduction in expression of proteases in clodrolip 
treated tumors partially confirmed TAM depletion (Lin et al. 2006, Gocheva et al. 
2010).  
Fibronectin can be expressed by mesenchymal stem cells, macrophages and 
mesenchymal tumor cells (Alitalo et al. 1980, Lerat et al. 1993, Nawshad et al. 
2005, Kalluri and Zeisberg, 2006). Its expression in tumor cells is often associated 
with loss of epithelial adherence junctions, mesenchymal trans-differentiation and 
acquisition migratory properties (Maeda et al. 2004). Indeed, the gene expression 
analysis revealed an inverse correlation between expression of the epithelial 
adherence molecule E-cadherin and fibronectin (Fig. 12B). Moreover, a number of 
genes involved in epithelial cell migration showed altered expression upon 
clodrolip treatment. The intermediary filaments vimentin and lamin A were both 
down regulated relative to control tumors (~ 2 fold, and ~ 5 fold, respectively).  
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Fig. 12. Clodrolip mediated TAM depletion correlates with gene expression patterns 
characteristic of epithelial cell migration. A. Relative fold gene expression (mRNA levels, micro 
array analysis) of factors involved in ECM remodeling in clodrolip treated vs. control F9-tumors; 
matrix metalloproteinase 14, (Mmp14), cathepsin b (Ctsb), cathepsin h (Ctsh), fibronectin (Fn) and 
laminin b  (Lamb); n=2, bars = ± SEM. B. Relative fold gene expression  (mRNA  levels,  micro 
array  analysis) of factors involved in epithelial cell migration in clodrolip treated vs. control F9-
tumors; E-cadherin (Cdh1), Vimentin (Vim), Lamin A (Lmna), CD44 (Cd44), Stathmin (Stmn1) and 
actin related protein 2/3 complex subunit 5 (Arp2/3); n=2, bars = ± SEM 
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Expression of the hyaluron receptor CD44, which is important for tumor cell 
migration, and the actin related protein 2/3 complex, regulating actin 
polymerization during migration, were similarly reduced ~7 fold and ~2.5 fold, 
respectively, upon clodrolip treatment (Fig. 12B), (Merzak et al. 1994, Mullins et al. 
1998, Kedrin et al. 2007, Outhit et al. 2007). In contrast, the migration inhibitor 
Stathmin 1 was expressed ~ 4 fold higher in clodrolip treated tumors relative to 
control tumors (Baldasarre et al. 2005). All together, the gene expression analysis 
uncovered a correlation between TAM infiltration and transcriptional regulation of 
genes involved in epithelial cell migration. In particular, the inverse correlation 
between E-cadherin and mesenchymal gene expression suggested a potential 
connection between TAM infiltration and tumor cell EMT. 
 
4.3 
Tumor associated macrophages regulate epithelial to mesenchymal 
transition in tumor cells in a TGF-β dependent manner 
The following section is adapted from a manuscript with the same title recently 
submitted to Clinical Cancer Research (Title page and abstract is enclosed in 
Appendix 3). 
 
4.3.1 
Depletion of TAMs reduces mesenchymal gene expression in murine F9-
teratocarcinomas in vivo 
To address the potential role of TAMs in tumor EMT, clodrolip treated and 
control F9-tumors were evaluated by q-PCR for gene expression of key markers 
for EMT (Fig. 13A). The analysis confirmed the micro array data, in that vimentin 
expression was reduced (~ 5 fold), whereas E-cadherin expression was increased 
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(~2 fold) in clodrolip treated tumors relative to controls. In addition, the 
mesenchymal cell adherence molecule N-cadherin was reduced ~ 2 fold in 
clodrolip treated tumors relative to controls (Maeda et al. 2004). Expression of the 
EMT associated transcription regulators Snail and Twist, both of which repress E-
cadherin transcription, were decreased ~2 fold and ~4 fold, respectively, in 
clodrolip treated tumors (Cano et al. 2000, Vesuna et al. 2008). Western blotting 
confirmed a relatively high expression of E-cadherin and its interaction partner β-
catenin in clodrolip treated tumors relative to controls (Fig. 13B). To test if the 
reduction in total β-catenin levels in control tumors correlated with an increase in 
the active form of β-catenin, an antibody specifically detecting the free, non-
phosphorylated form (active β-catenin) was used. However, quantification of the 
western blot failed to establish obvious differences in the levels of active β-catenin 
between controls and clodrolip treated tumors (Fig. 13C). Immunohistochemical 
analysis of the F9-tumors elucidated a correlation between tumor cell expression 
of selected EMT markers and CD68+ macrophage density (Fig. 13D). Whereas E-
cadherin and β-catenin localized to the cellular membrane of tumor cells in areas 
with low CD68+ densities, both proteins were partially lost in areas with high 
CD68+ densities. Conversely, fibronectin expression was increased in CD68+ rich 
areas. TAM density thus correlated with a mesenchymal-like tumor cell phenotype 
in F9-teratocarcinoma tumors.   
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Fig. 13. Depletion of TAMs reduces mesenchymal gene expression in F9-teratocarcinomas. 
A. Fold gene expression (mRNA levels, q-PCR analysis) of E-cadherin (Cdh1), vimentin (Vim), N-
cadherin (Cdh2), Snail (Snai1) and Twist (Twist1) in clodrolip treated vs. control F9-tumors; n=5-6, 
bars: ± SEM. B. Western blotting analysis of E-cadherin, total β-catenin and active β-catenin 
expression in control and clodrolip treated F9-tumors; n=5. C. Quantification of B. Mean values in 
each group are indicated. D. Immunohistochemical analysis of CD68+ macrophages (green), E-
cadherin (red), β-catenin (red) and fibronectin (red) expression in a macrophage poor area (left 
panel) and a macrophage rich area (right panel) in a control F9-tumor section. The nuclei were 
stained with DAPI (blue). Scale bar=0.02 mm.  
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4.3.2 
The macrophage secretome incites tumor cell invasion through induction of 
EMT in vitro 
Having identified a correlation between TAM density and tumor cell EMT in 
vivo, 2D culture techniques were used to further characterize the mechanisms of 
action through which TAMs regulate this process. As the F9-teratocarcinoma cell 
line is highly sensitive to cytokine signaling in vitro as well as in vivo, it represents 
a potent cell culture model for EMT associated research (Krawitz and Kelly, 2008). 
In addition, the murine epithelial mammary gland NMuMG-cell line was used as it 
provides a model that is well characterized in the context of EMT (Bakin et al. 
2000, Bhowmick et al. 2001, Gal et al. 2008, Vincent et al. 2009). The F9- and 
NMuMG-cells were cultured in conditioned medium generated by F9-cells (F9-CM) 
or NMuMG-cells (N-CM), or in medium conditioned by M2 polarized RAW264.7 
macrophages (M-CM) (Wang et al. 2007). The cells were analyzed by 
immunofluorescence for morphology and cellular localization of E-cadherin, β-
catenin, vimentin and fibronectin (Fig. 14A and 14E). Both cell lines displayed an 
epithelial morphology when cultured in F9-CM or N-CM. E-cadherin and β-catenin 
localized to the cellular membrane and vimentin and fibronectin were expressed at 
low levels. A similar profile was observed in cells cultured for 24 hours in M-CM. 
However, after long term culture in M-CM (7 days for F9-cells, 13 days for 
NMuMG-cells) the cells acquired an elongated fibroblast-like morphology. This 
morphological change correlated with partial loss of epithelial adherence junctions, 
reduced E-cadherin expression, cytoplasmic localization of β-catenin and 
increased levels of active β-catenin (Figs. 14B, 14F and suppl. Fig. S1). Moreover, 
the expression levels of vimentin and fibronectin were increased (Figs. 14A, 14E).  
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Fig.14. M-CM-induced EMT correlates with activation of the β-catenin pathway and 
increased invasion of F9-cells and NMuMG-cells in vitro. A. Immunofluorescence analysis of E-
cadherin, β-catenin, vimentin and fibronectin expression and cellular localization in F9-cells 
cultured in F9-CM or M-CM for 24h and 7d. After 7d of culturing, the M-CM was substituted with 
F9-CM for another 7 days prior to immunohistochemical analysis of E-cadherin and β-catenin 
expression. Scale bar=0.02 mm. Proteins were stained red. Nuclei were stained with DAPI (blue). 
B. Protein expression (quantified from western blots shown in suppl. Fig.2) of E-cadherin and total 
β-catenin in F9-cells cultured in F9-CM or M-CM for 6h, 24h, 5d, and 7d. After 7d of culture, the F9-
cells were cultured for another 7d in F9-CM. C. Fold luciferase expression 
(TOPFLASH/FOPFLASH) in F9- cells after 7d of culture in F9-CM or M-CM; n=7; * indicates p < 
0.05. ** indicates p<0.005, unpaired t-test; bar=±SEM. D. Relative fold invasion by F9-cells in 
response to F9-CM or M-CM (48h, 1% Matrigel); n=8. Relative invasion was normalized to F9-CM 
or N-CM. ** indicates p < 0.005, unpaired t-test; bar=±SEM.  
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Fig.14 continued. E. Immunofluorescence analysis of E-cadherin, β-catenin, vimentin and 
fibronectin expression and cellular localization in NMuMG-cells cultured in N-CM or M-CM for 24h 
or 13d. Scale bar=0.02 mm. Proteins were stained red. Nuclei were stained with DAPI (blue). F. 
Protein expression (quantified from western blots shown in suppl. Fig.2) of E-cadherin and total β-
catenin in NMuMG-cells cultured in N-CM or M-CM for 6 h, 24h, 7d and 13d. G. Fold luciferase 
expression (TOPFLASH/FOPFLASH) in NMuMG-cells after 13d of culture in N-CM or M-CM; n=7; * 
indicates p < 0.05. ** indicates p<0.005, unpaired t-test; bar=±SEM. H. Relative fold invasion by 
NMuMG-cells in response to F9-CM, N-CM or M-CM (48h, 1% Matrigel); n=3. Relative invasion 
was normalized to F9-CM or N-CM. ** indicates p < 0.005, unpaired t-test; bar=±SEM.  
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Interestingly, the phenotypic shift induced by M-CM was reversible in F9-cells. 
In a time depend manner, the expression levels of E-cadherin and membranous β-
catenin were re-established and the level of active β-catenin was markedly 
reduced upon removal of M-CM (Figs. 11A lower panel and 14B left panel).  
To confirm that the β-catenin pathway was transcriptionally activated upon 
release from the plasma membrane, the TOPFLASH/FOPFLASH reporter assay 
was implemented (Korinek et al. 1997). The TOPFLASH construct expresses 
luciferase downstream of a triple wild type Tcf-binding site, whereas the 
FOPFLASH construct is mutated at these binding sites and thus provides a 
negative control for the readout. Using this assay a significant increase in 
transcription activity of the β-catenin/Tcf complex in response to long term M-CM 
culturing was confirmed (p<0.05, unpaired t-test), (Fig. 14C and 14G).  
One possible consequence of EMT is increased tumor cell invasion (Bakin et 
al. 2000, Lu et al. 2003, Nawshad et al. 2005, Yang and Weinberg, 2008, Thiery et 
al. 2009). Therefore, the invasive properties of F9- and NMuMG-cells were 
assessed in an in vitro invasion assay using Matrigel coated transwells. Both cell 
lines displayed significantly increased invasive properties in response to M-CM 
(p<0.05, unpaired t-test), (Fig. 14D and 14H). Thus, the M-CM induced 
mesenchymal phenotype correlated with an activation of the β-catenin pathway 
and increased invasive properties in both cell lines. As the cells never were in 
physical contact with macrophages, we concluded that the invasive, mesenchymal 
cell phenotype was regulated by soluble macrophage-derived cytokines.  
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4.3.3 
Polarized macrophages regulate EMT in F9- and NMuMG-cells in a TGF β1 
dependent manner 
We next sought to identify the putative cytokine(s) involved in this process. 
The F9-tumors were evaluated for gene expression of four established inducers of 
EMT and invasion; Wnt5a, Tgf-β1, Tgf-β2 and Egf (Gazit et al. 1999, Bakin et al. 
2000, Bhowmick et al. 2001, Pukrop et al. 2006, Gal et al. 2008, Vincent et al. 
2009). Whereas Wnt5a expression was too low for detection by q-PCR, Egf levels 
were ~ 3 fold decreased and Tgf-β1 and Tgf-β2 were ~ 2 fold decreased in 
clodrolip treated tumors relative to controls (Fig. 15A and suppl. Fig. S2). As TAMs 
are a main source of both EGF and TGF-β1 in the tumor microenvironment, these 
two candidates were further investigated (Yang et al. 2008, Yang and Weinberg, 
2008). Both cell lines were cultured in DMEM medium +/- recombinant EGF 
(rEGF, 50 ng/ml) or DMEM medium +/- recombinant TGF-β1 (rTGF-β1, 2 ng/ml). 
The cells were analyzed by immunofluorescence for expression and localization of 
E-cadherin, β-catenin, vimentin and fibronectin (Fig. 15B and suppl. Fig. S3). Only 
rTGF-β1 induced a mesenchymal phenotype in the two cell lines. This phenotypic 
shift correlated with increased β-catenin/Tcf transcription activity (Fig. 15C). 
However, rEGF alone was sufficient to activate the MAP-kinase pathway 
downstream of the EGF-receptor in both cell lines, confirming that EGF receptors 
were functional (suppl. Fig. S4). 
TGF-β mediates EMT partially through activation of the PI3K/Akt-pathway 
(Bakin et al. 2000, Nawshad et al. 2005). Western blotting analysis confirmed the 
activation of this pathway in F9-cells in response to 7 days of culture in DMEM +  
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Fig.15. Recombinant TGF-β1 induces an EMT associated phenotype in F9- and NMuMG-cells in 
vitro. A. Relative fold gene expression (mRNA levels, qPCR analysis) of Egf, Tgf-β1 and Tgf-β2 in 
clodrolip treated vs. control F9-tumors; n=5-6, bars:±SEM. B. Immunofluorescence analysis of E-
cadherin, β-catenin, vimentin and fibronectin expression and cellular localization in F9-cells cultured in 
DMEM +/- EGF (50 ng/ml) and DMEM +/- TGF-β1 (2 ng/ml) for 7d. Scale bar=0.02 mm. Proteins were 
stained red and nuclei were stained with DAPI (blue). C. Fold luciferase expression 
(TOPFLASH/FOPFLASH) in F9- (upper panel, n=5) and NMuMG-cells (lower panel, n=3) after 7d or 
13d, respectively, of culture in DMEM+/- EGF or +/- TGF-β1. * indicates p < 0.05, unpaired t-test, 
bar=±SEM.  
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rTGF-β (Fig. 16A). Interestingly, M-CM activated this pathway in F9-cells as well, 
and the activation was abrogated when M-CM was neutralized for TGF-β (Fig. 
16A). To test if neutralization of TGF-β was sufficient to abrogate M-CM induced 
EMT, F9- and NMuMG-cells were cultured in M-CM neutralized for TGF-β and 
subsequently analyzed for EMT marker expression by immunofluorescence. Both 
cell lines maintained an epithelial morphology and phenotype after 7 and 13 days 
of culture, respectively (Fig. 16B and suppl. Fig. S5). Concordantly, transcriptional 
activity of the β-catenin/Tcf complex resembled that of control cells (Fig. 16C). 
Lastly, TGF-β-neutralization significantly reduced the invasive properties of both 
cell lines in response to M-CM (Fig. 16D). However, when used as an exogenous 
chemoattractant TGF-β1 did not induce cell invasion (suppl. Fig. S6). Thus, 
macrophage-derived TGF-β regulated cell invasion through induction of an 
invasive cell phenotype. 
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Fig. 16. Neutralization of TGF-β1 abrogates the M-CM induced EMT phenotype. A. Western 
blotting analysis of phospho-Akt  (S473) in F9-cells after 24h and 7d of culture in M-CM, DMEM +/- 
TGF-β1, F9-CM and M-CM neutralized for TGF-β. B. Immunofluorescence analysis of E-cadherin, 
β-catenin, vimentin and  fibronectin expression and cellular localization in F9-cells cultured for 24h 
and 7d in M-CM neutralized for TGF-β. C. Fold luciferase expression (TOPFLASH/FOPFLASH) in 
F9- (left) and NMuMG-cells (right) after 7d and 13d of culture in F9-CM, N-CM or M-CM neutralized 
for TGF-β, respectively; n=4, p > 0.05, unpaired t-test, bars=±SEM. D. Relative fold invasion by F9- 
(left) and NMuMG-cells (right) in response to M-CM +/- TGF-β neutralizing antibody (48h, 1% 
Matrigel), n=2, * indicates p < 0.05, unpaired t-test, bar=±SEM.    
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4.3.4 
CD68+ macrophage density correlates with mesenchymal tumor cell 
phenotype and tumor grade in NSCLC patients 
Soltermann and collaborators have previously demonstrated a significant 
correlation between tumor cell expression of selected EMT-markers and various 
clinico-pathologic parameters for tumor progression in NSCLC patients 
(Soltermann et al. 2008). In this study we used NSCLC as a model to address the 
clinical relevance of intra-tumoral macrophages in tumor cell EMT. To this end, 
two independent researchers analyzed 491 NSCLC tissue samples of which 228 
were adenocarcinomas (AC), 244 squamous cell carcinomas (SCC) and 19 
adeno-squamous carcinomas (ASQ). Intra-tumoral macrophage density correlated 
significantly with tumor grade (Spearman correlation, SC>0.2), but not with other 
clinico-pathologic parameters for tumor progression like tumor stage (pT), lymph 
node metastasis/nodal stage (pN), and metastasis (pM), or tumor size (Table 2).  
The tissue samples were further analyzed for tumor cell expression of 
EMTassociated markers (Table 3 and Fig. 17). Membranous E-cadherin and 
membranous β-catenin were chosen as epithelial markers, whereas cytoplamic 
vimentin, cytoplasmic periostin and cytoplasmic β-catenin were chosen as 
mesenchymal markers. Both evaluations established a moderate, positive 
correlation between intra-tumoral CD68+ macrophage density and mesenchymal 
marker expression in tumor cells (SC>0.2). Moreover, CD68+ macrophage density 
correlated negatively with membranous β-catenin in both evaluations (SC>-0.2). 
E-cadherin likewise showed a modest negative correlation with CD68+ 
macrophage density in evaluation 1 (SC>-0.2), however, evaluation 2 could not 
confirm this correlation. Finally, tumor cell expression of mesenchymal markers 
correlated positively with tumor grade (SC<0.2). The data established a significant 
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and clinically relevant correlation between TAM infiltration, EMT associated tumor 
cell phenotype and tumor grade.  
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Table 2. Clinico-pathologic parameters and CD68+ tumor infiltration 
 
AC: Adenocarcinoma, SCC: Squamous cell carcinoma, ASQ: Ademosquamous carcinoma. 
 * indicates G1 and G2 versus G3. 
Note: p-values and spearman correlation values (SC) are indicated.  
Statistical analysis was performed in SPSS 16.0 for windows. 
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Fig.17. High intra-tumoral CD68+ macrophage density correlates with mesenchymal protein 
expression in NSCLC patient samples. NSCLC tissue sections stained for CD68, E-cadherin, β-
catenin and vimentin. NSCLC tumor 1 is  an adenocarcinoma of solid subtype, NSCLC tumor 2 is 
an adenocarcinoma of  glandular subtype. NSCLC tumor 1 is a score 2 for CD68, score 1 for  
membranous E-cadherin, score 2 for membranous β-catenin, score 3 for cytoplasmic β-catenin and 
score 3 for vimentin. NSCLC tumor 2 is a score 1 for CD68, score 3  for membranous  E-cadherin, 
score 3 for membranous β-catenin, score 1 for cytoplasmic β-catenin and score 0 for vimentin. 
Pictures were acquired with 20X magnification. 
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Table 3. EMT associated protein markers and CD68+ tumor infiltration 
 
 
Note: p-values and spearman correlation values (SC) are indicated.  
Statistical analysis was performed in SPSS 16.0 for windows 
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5 Discussion 
   
5.1 
Identifying novel implications of TAMs in tumor progression  
The main focus of this study was to identify and characterize novel roles for 
TAMs in tumor progression. For this purpose, a micro array analysis of F9-
teratocarcinomas infiltrated by – or depleted of – TAMs was performed. Depletion 
of TAMs was confirmed by a noticeable reduction in monocyte/ macrophage 
specific markers in clodrolip treated tumors. TAMs are well known regulators of 
tumor angiogenesis and ECM remodeling, thus to confirm the functional 
consequences of TAM depletion, genes involved in these processes were 
analyzed (Hagemann et al. 2004, Lin et al. 2006, Pollard, 2009, Gocheva et al. 
2010). To this end, expression of genes involved in the angiogenic process and 
ECM remodeling was reduced as a consequence of clodrolip treatment.  
A striking difference between the control and the clodrolip treated tumors was 
the expression of the epithelial marker E-cadherin, which correlated negatively 
with the expression of TAM markers. Loss of E-cadherin is a prerequisite for 
epithelial cell migration, and the micro array data revealed an inverse correlation 
between E-cadherin expression and expression of genes directly involved in the 
cytoskeleton changes required for successful migration, such as Arp2/3, CD44 
and vimentin. It is of importance to note that macrophage migration is facilitated by 
similar molecular mechanisms, and the changes in expression of genes involved 
in this process can in part be due to the physical depletion of TAMs (Martise et al. 
2009, Yilmatz and Christofori, 2009). Nevertheless, the observed reduction in 
expression of pro-migratory genes, in concert with the relative increase in E-
cadherin and stathmin expression in TAM depleted tumors, suggested a potential 
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involvement of TAMs in regulation of pathways modulating epithelial cells 
migratory properties. 
 
5.2 
TAMs regulate EMT in epithelial tumor cells 
Among the genes down-regulated in TAM depleted tumors were the 
mesenchymal markers vimentin and fibronectin as well as the CD44 receptor, 
which is an important mediator of cell invasion (Merzak et al. 1994, Korinek et al. 
1997, van de Wettering et al. 2002, Marhaba and Zöller, 2004, Schmidt-Ott et al. 
2007). Moreover, q-PCR analysis of the F9-tumors uncovered negative 
correlations between gene expression of E-cadherin and N-cadherin, snail and 
twist. The “cadherin switch” as well as the increase in mesenchymal gene 
expression and concordant up-regulation of snail and twist are molecular 
hallmarks of EMT (Maeda et al. 2004, Nawshad et al. 2005). Thus our data hint 
towards a link between TAMs and EMT mediated trans-differentiation in tumors 
cells. 
Western blotting analysis of whole tumor extracts confirmed an increase in E-
cadherin and total β-catenin levels in TAM depleted tumors relative to controls. As 
β-catenin can become transcriptionally active upon dissociation from E-cadherin, 
the levels of active β-catenin were tested by western blotting using an antibody 
specifically recognizing the active form of β-catenin (Korinek et al. 1997, Nawshad 
et al. 2005, Yilmatz and Christofori, 2009). However, the western blotting 
technique failed to confirm any correlation between E-cadherin and active β-
catenin in whole tumor extracts. EMT is by nature transient, and the transcriptional 
onset of an EMT program is therefore difficult to trace in whole tumor extracts 
(Nawshad et al. 2005). Moreover, immunohistochemical analysis of frozen tumor 
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sections revealed a correlation between TAM density and mesenchymal tumor cell 
phenotype. This observation suggests that TAMs either recruit mesenchymal 
tumor cells or that they modulate the phenotype of the cells located predominantly 
in the neighboring microenvironment. Due to the rather small population of 
mesenchymal tumor cells, the fraction of active β-catenin may have been too low 
for detection by western blotting. The observation that TAM density correlated with 
a predominant mesenchymal tumor cell phenotype located in the neighboring 
environment suggests a causal relationship between tumor cell phenotype and 
TAM infiltration. TAMs are highly represented in the invasive front of solid tumors, 
thus the possibility that TAMs can modulate tumor cell phenotype locally can help 
to explain the poorly understood phenomenon of mesenchymal-like tumor cells 
often found to accumulate in the invasive tumor front (Brabletz et al. 2001, Franci 
et al. 2006, Sheehan et al. 2008, Joyce and Pollard, 2009).  
TAMs ability to induce an EMT associated phenotypic shift was further 
investigated in F9- and NMuMG cells in vitro. In contrast to the heterogeneous 
tumor tissues, analysis of cell cultures confirmed a TAM dependent activation of 
the β-catenin pathway. This was further supported by immunofluorescence 
analysis, which revealed a macrophage culture medium (M-CM) dependent up-
regulation of the β-catenin target genes, vimentin and fibronectin (Schmidt-Ott et 
al. 2007). Interestingly, the EMT transcription program, as well as the 
mesenchymal phenotype as evaluated by immunofluorescence, was reversible in 
F9-cells upon removal of M-CM. Mesenchymal cells of epithelial origin can re-
acquire epithelial traits by undergoing MET. MET has been assigned with a 
hypothetical role in metastatic colony formation where plastic tumor cells in 
response to microenvironmental changes become epithelial and start colonizing 
the host tissue (Thiery, 2002, Hugo et al. 2007, Yang and Weinberg, 2008). MET 
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may also be of importance for local tumor invasion where tumor cells transiently 
acquire migratory properties to move across tumor boundaries and invade the 
hosting tissue (Thiery, 2002, Hugo et al. 2007). The reversibility of M-CM induced 
mesenchymal phenotype therefore suggests that TAMs contribute to tumor cell 
plasticity through regulation of EMT/MET. 
 
5.2.1 
TAMs signal EMT through TGF-β1 
A number of in vivo studies have correlated TAM-infiltration into solid 
tumors with metastasis (Yang et al. 2008, Quian et al. 2009). In this respect, 
TAMs have been identified as a major source of chemokines that attract and 
recruit migratory tumor cells to distant sites (Wyckoff et al. 2004, Green et al. 
2009). Concordantly, M-CM significantly stimulated the invasive properties of 
F9- and NMuMG-cells in vitro. In a candidate based screen, macrophage 
derived TGF-β was identified as the main cytokine inducing invasion in these 
cell lines, and neutralization of TGF-β1 in M-CM significantly reduced the 
invasive properties of the cells. However, rTGF-β1 alone did not prove to be a 
potent chemoattractant. These findings suggest that TGF-β regulates tumor cell 
invasion by induction of a chemotactic phenotype, rather than providing the 
chemoattracting signal itself. Immunofluorescence analysis of F9- and NMuMG-
cells cultured in DMEM+/rTGF-β further support this notion, as rTGF-β potently 
induced a mesenchymal-like phenotype in the two cell lines. Collectively, the 
data demonstrate a direct involvement of TAMs in intrinsic regulation of invasive 
properties in tumor cells. TAMs are a significant stromal source of 
chemoattractants such as SDF-1, VEGF and EGF, and the data at present 
therefore suggest a model in which TAMs, through TGF-β signaling, can induce 
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an invasive phenotype via EMT, and concurrently provide chemokines to attract 
the invasive tumor cells (Fig. 18), (Wyckoff et al. 2004, Green et al. 2009).  
TGF-β1 is a multifaceted regulator of EMT. On one hand, it directly induces 
EMT through activation of the TGF-β receptor. On the other, it stimulates the 
production of MMPs in an autocrine and paracrine fashion (Kim et al. 2007, 
Labbé et al. 2007, Uttamsingh et al. 2008). MMPs are important in this context 
as they are essential for proteolytic degradation of the ECM and thus contribute 
to increase the bioavailability of growth factors. Moreover, E-cadherin is a well 
established substrate for MMPs, and cleavage of E-cadherin can be sufficient to 
induce EMT (Radisky et al. 2005, Orlichenko and Radisky, 2008). The notion 
that TAMs induce EMT in a TGF-β dependent manner proposes that TAMs 
essentially orchestrate tumor cell invasion through activation of multiple EMT 
inducing pathways.  
Although being a strong mediator of EMT, TGF-β often signals in 
conjunction with other cytokines such as Wnt and EGF in vivo (Nawshad et al. 
2005, Labbé et al. 2007, Uttamsingh et al. 2008). It was therefore surprising to 
find that neutralization of TGF-β1 in M-CM was sufficient to abrogate the 
invasive, mesenchymal cell phenotype. Although synergistic effects between 
TGF-β1 and other macrophage-derived cytokines cannot be excluded, we can 
conclude that TGF-β1 is indispensable for the induction of EMT in F9- and 
NMuMG-cells. Whether TGF-β is indispensable for EMT induction in vivo is yet 
to be investigated. 
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Fig. 18. Schematic illustration presenting the current model of TAM regulated tumor cell 
invasion. Epithelial cancer cells recruit and stimulate TAMs through cytokine signaling and TAMs 
respond by providing the microenvironment with TGF-β. TGF-β activates the TGF-β1/2 receptors in 
a paracrine fashion and through canonical and non-canonical signaling E-cadherin is suppressed, 
β-catenin is released and translocates to the nucleus to initiate the EMT transcription program. 
Consequently, the cytoskeleton is reorganized and the cell morphology changes from apicobasal to 
fibroblastoid. TGF-β furthermore stimulates the production of MMPs in a paracrine and autocrine 
fashion, and thus contributes significantly to the remodeling of the ECM and local invasion by tumor 
cells. Lastly, infiltrated TAMs can attract invasive tumor cells through secretion of chemokines. 
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5.2.2 
TAM density correlates with mesenchymal tumor phenotype in NSCLC 
patients 
An important aspect of this study was to address the clinical relevance of 
TAMs in regulation of tumor associated EMT. Soltermann and colleagues have 
previously proposed the mesenchymal proteins vimentin, periostin and the 
putative MET marker versican as prognostic markers for NSCLC (Soltermann et 
al. 2008). This was based on the observation that expression of these 
mesenchymal proteins in tumor cells correlated significantly with a number of 
clinico-pathologic parameters and disease outcome. In the current study, the 
correlation between intra-tumoral CD68+ macrophage density and a 
mesenchymal tumor cell profile was evaluated. In concordance with the murine 
data, the NSCLC study revealed a positive, significant correlation between 
CD68+ macrophage density and EMT-status of tumor cells in the local 
microenvironment. Moreover, both CD68+ density and pronounced 
mesenchymal tumor profile correlated with tumor grade, confirming the clinical 
relevance of our in vitro and in vivo findings.  
The correlation between mesenchymal tumor profile and tumor grade 
suggests a possible link between tumor de-differentiation and EMT-mediated 
trans-differentiation. Although being highly speculative, this potential connection 
should be further investigated as it may provide important information to 
increase the general understanding of the poorly understood de-differentiation 
process of epithelial tumors.  
TAM infiltration and tumor cell EMT are generally associated with metastatic 
disease, however the data obtained in this study provide no evidence for such a 
correlation. It is here important to note that the metastatic process is complex 
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and not solely depends on these two factors (Yang and Weinberg, 2008, Joyce 
and Pollard, 2009).  
 
5.3 
Conclusions 
The data presented here provide functional evidence for a regulatory role of 
TAMs in tumor cell EMT. Moreover, the identification of a correlation between 
intra-tumoral macrophage densities, EMT associated tumor profile and tumor 
grade in NSCLC patients confirms the clinical relevance of this finding.  
Interestingly, recent reports have suggested that the mesenchymal tumor cell 
phenotype is related to the cancer stem cell phenotype and genomic instability, 
and it has been speculated that therapies abrogating EMT may lead to 
improved cancer management (Radisky et al. 2005, Mani et al. 2008, Thiery et 
al. 2009, Polyak and Weinberg, 2009). Data presented here contribute to 
increase our current understanding of the complex tumor-stroma interplay and 
provide novel insight valuable for the development of therapies abrogating 
EMT-associated disease progression.  
 
5.4 
Future perspective 
Presently, the link between TAM-induced tumor cell EMT and invasion was 
investigated in vitro. Although the consequences of EMT in terms of invasion 
are generally accepted it is of great importance to confirm this link in vivo 
(Nawshad et al. 2005, Yang and Weinberg, 2008).  
In this study I chose a subcutaneously implanted murine F9-teratocarcinoma 
model for in vivo investigations. Subcutaneous tumors generally lack invasive 
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fronts, and it is therefore impossible to draw substantial conclusions from these 
data regarding the role of TAM regulated EMT during local tumor invasion in 
vivo. This issue can be overcome by studying the phenomenon in orthotopic or 
spontaneously growing tumor models.  
The murine, orthotopic 4T1 mammary carcinoma model is a highly invasive 
and metastatic model in which invasion was recently shown to be dependent on 
TGF-β signaling (Pulaski and Ostrand-Rosenberg, 2001, Fantozzi and 
Christofori, 2006, Bandyopadhyay et al. 2010). Due to its susceptibility to 
growth factor signaling, the orthotopic nature of the model and the fact that 
mammary tumors generally are infiltrated by TAMs, 4T1 may be a suitable 
model for such studies (Pulaski and Ostrand-Rosenberg, 2001, Leek and 
Harris, 2002). Moreover, this model forms spontaneous metastasis, which 
further facilitates investigations of the implication of TAMs and EMT in the 
metastatic process (Pulaski and Ostrand-Rosenberg, 2001, Fantozzi and 
Christofori, 2006, Bandyopadhyay et al. 2010).  
The recent finding that EMT generates mesenchymal tumor cells with stem 
cell properties is very exciting (Mani et al. 2008, Polyak and Weinberg, 2009, 
Reiman et al. 2010, Santisteban et al. 2010). Cancer stem cells are highly drug 
resistant and they are believed to contribute significantly to patient relapse. It 
would therefore be interesting to perform a therapy study, in which TAM-
depletion would be combined with a standard chemotherapy to test if TAM-
depletion would increase the general tumor response to the treatment and 
prevent disease recurrence.   
EMT is required for inflammation-induced cell migration and wound healing 
(Wu et al. 2009). This finding directly links the mechanism to pre-cancerous 
lesions, where EMT may be induced in response to pro-inflammatory signaling 
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(Wu et al. 2009, Toblar et al. 2010). Moreover, both EMT and inflammation 
have been linked to genomic instability, thus taken together, these independent 
studies suggests that EMT may contribute to the transforming events occurring 
during inflammation (Radisky et al. 2005, Colotta et al. 2009, Wu et al. 2009, 
Toblar et al. 2010). Although being highly speculative, this idea may provide an 
attractive model, in which therapeutic targeting of TAMs and/or their secretome 
may prevent transformation of pre-cancerous lesions. As this model is highly 
speculative, the possible link between TAM induced EMT and tumor initiation 
should be investigated carefully. 
The identification of TAMs as stromal regulators of tumor cell EMT provide 
novel information to increase our understanding of the complex tumor-stroma 
crosstalk. However, it also raises new and interesting questions concerning the 
implications and regulation of TAMs and EMT in disease progression, and these 
questions should be addressed experimentally within the near future.    
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6. Materials and Methods 
 
Antibodies and reagents  
Primary antibodies were all anti-mouse: Anti-rat-E-cadherin (Abcam), anti-
rabbit-β-catenin (Sigma), CD68-Alexa-488 (Serotec ABD), F4/80-Alexa-647 (AbD 
Serotec), anti-mouse-active-β-catenin (Millipore), anti-rabbit-β-actin (Abcam), anti-
mouse-vimentin (Abcam), anti-rabbit-fibronectin (Abcam), anti-rabbit-AKT-
phospho-S473 (Abcam). Secondary antibodies used: Goat-anti-rat-IgG-TRITC 
(Sigma), chicken-anti-rabbit-Alexa-594 (Molecular Probes), biotin-SP-Donkey-Anti-
Rabbit-IgG, biotin-SP-donkey-anti-rat-IgG, and biotin-SP-donkey-anti-mouse-IgG 
(Jackson ImmunoResearch Laboratories). Streptavidin-HRP (Biolegends) was 
used to detect biotin labeled secondary antibodies. Recombinant TGF-β1 and 
TGF-β neutralizing antibody were purchased from R&D Biosystems and 
recombinant EGF was kindly provided by Dr. A. Mueller, IMCR, University of 
Zürich, Switzerland.  
 
Cell lines and conditioned medium  
F9-teratocarcinoma cells (ATCC CRL-1720) were grown on 0.01% gelatin. 
NMuMG-cells (CRL-1636) were kindly provided by Prof. G. Christofori, Center for 
Biomedicine, University of Basel, Switzerland. Both cell lines were cultured at 
37°C, 5% CO2, in DMEM/10% FBS/0.8% penicillin-streptomycin. RAW264.7 
macrophages (Sigma) were cultured at 37°C, 5% CO2, in RPMI1640/10% 
FBS/0.8% penicillin-streptomycin/1% Na-pyruvate (GIBCO). Conditioned medium 
was generated by culturing cells at 80% confluency in DMEM/10%FBS/ 0.8% 
penicillin-streptomycin for 24h. Collected conditioned medium was sterile filtered 
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prior to use (0.45µm pore size). RAW264.7 macrophages were polarized as 
previously described (Wang et al. 2007). 
 
F9-tumors and macrophage depletion  
F9-tumors were generated in female SV129S1 mice (Charles River, Germany) 
and liposomes were prepared as previously described (Zeisberger et al. 2006). 
Mice were kept in standard housing and normal diet at the animal facility of the 
University of Zürich. Animal studies were approved by the Veterinary Department 
of the Canton Zürich, Switzerland and performed under license 183/2006 issued to 
R.A. Schwendener. The control group (n=6) received empty liposomes (100 µl/20g 
body weight, i.p.), the test group (n=6) Clodrolip (1.5 mg clodronate/ 20g body 
weight, i.p.) starting 6h post tumor inoculation followed by the same dosage every 
3rd day for 20d. Tumor size was measured with a caliper and volumes were 
calculated according to V=πLW2/6 (L = largest tumor diameter, W = perpendicular 
diameter). Twenty four  hours after the last i.p injection the study was terminated 
and tumors were collected for subsequent analysis Tumors subjected to 
immunohistochemistry and protein chemistry were stored in Hanks salt buffer 
(GIBCO) at -80°C. Tumors subjected to q-PCR were stored in RNAlater as 
described by the provider (Qiagen).  
 
Immunohistochemistry of frozen F9-tissue sections  
Frozen sections (8 µm thickness) were acetone fixed, blocked with 1% 
BSA/TBS, incubated with primary and secondary antibodies (diluted as 
recommended by the provider) overnight at 4°C. Nuclei were stained with DAPI (1 
µg/ml). The sections were mounted with Vectashield (Vector labs) and visualized 
with an Olympus fluorescence microscope (1X81) using the CellR software 
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(Olympus). Pictures were acquired with 1x1 binning and 15x or 150x magnification 
at exposure times of 49-56 ns for DAPI and 500-550 ns for TRITC, Alexa-488, 
Alexa-594 and Alexa-647. The pictures were merged in Adobe Photoshop CS4.  
 
In vitro induction of EMT and immunofluorescence analysis of F9- and 
NMuMG-cells  
F9- and NMuMG-cells were cultured on sterile glass coverslips in F9-CM or N-
CM, M-CM +/- TGF-β neutralizing antibody (30 ng/ml), DMEM/10%FBS +/- rEGF 
(50 ng/ml) or +/- rTGF-β1 (2 ng/ml). The medium was renewed every 24h. The 
cells were harvested at the time points annotated, fixed with 3% formaldehyde, 
stained and visualized as described for frozen sections.  
 
In vitro invasion assay 
The cells were starved in serum free medium for 6h and seeded (100.000 
cells/well) in Boyden chambers (Corning, 8 µm pore size) coated with 50µl 1% 
Matrigel (BD Biosciences). F9-CM or N-CM and M-CM +/-TGF-β neutralizing 
antibody (30 ng/ml) were used as chemoattractants. The assay was incubated for 
48h at 37°C, 5% CO2. The relative number of invading cells was estimated by 
resazurin live cell detection using providers protocol (Invitrogen). The relative fold 
invasion was normalized to control conditions.   
 
Live cell viability assay 
Tumor polarized RAW 264.7 (IL-4/IL-13 polarized as described by Wang et al. 
2007) cells were seeded in 96 well plates (10`000 cells/well) and grown under 
standard conditions for 24 hours. The growth medium was renewed and varying 
concentrations of Clodrolip or empty liposomes (0-16 mM) were added directly into 
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the medium. The cells were cultured for additional 24 hours, washed, and the 
relative number of live cells was estimated by resazurin live cell detection using 
providers protocol (Invitrogen).  
 
Microarray preparation and analysis 
Total mRNA was isolated from homogenized F9-tumors using the RNAeasy kit 
(Qiagen). The quality of the mRNA was tested using the Experion RNA Std Sense 
Analysis kit/Bioanalyser following the providers protocol (Bio-Rad). Samples that 
showed good quality were submitted to the Functional Genomics Center Zurich, 
University of Zurich, Switzerland, under the project number 175, for microarray 
chip analysis (Affymetrix). Target genes exceeding a threshold of > 2 fold +/- were 
selected and screened for pathway-involvement using ermine 2.1.1.5 (free 
software from Columbia University, NY, USA).  
 
NSCLC tissue microarrays and patient cohort  
The selection of NSCLC patient tissue samples and generation of the tissue 
microarrays (TMAs) were done as previously described (Soltermann et al. 2008). 
In brief, formalin-fixed and paraffin-embedded tumor tissue samples of 532 
NSCLC patients were reviewed by two pathologists and two representative tissue 
cores (0.6 mm) were assembled into 3 TMAs. Patients having obtained neo-
adjuvant chemotherapy were excluded. Sarcomatoid carcinomas were excluded 
from this study and EMT was strictly defined by expression of EMT-associated 
protein markers and not by morphology (number of final samples = 491). The 
study was approved by the institutional review board of the University Hospital 
Zürich under reference number StV-29-2009.  
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NSCLC, immunohistochemistry  
Immunohistochemistry on 4 μm sections from the TMA blocks was performed 
using automated platforms from either Ventana (Ventana Medical Systems) or 
Bond (Vision Biosystems). Following primary monoclonal antibodies were used: 
anti-CD68 (DAKO-Cytomation, clone PG-M1, 1:50 dilution), anti-E-cadherin (Cell 
Marque, clone EP700Y, 1:200), anti-β−catenin (BD Transduction laboratories, 
clone 14, 1:50), anti-vimentin (DAKO-Cytomation, 1:250) and Pab anti-periostin 
(BioVendor, 1:500). Detection was performed using the UltraVIEW-DAB (Ventana) 
or the Refine-DAB (Bond) detection kits, including respective secondary antibodies 
as described before (Soltermann et al. 2008).  
 
NSCLC, interpretation and statistical methods  
Distinct intra-epithelial CD68+ macrophage density was semi quantitatively 
scored by AKB and by two pathologists (VT and AS) on a multi-headed 
microscope (Zeiss Axioscope 2 MOT) using a four-tiered system: 0 (negative), 1+ 
(few to some CD68+ macrophages), 2+ (moderate number of CD68+ 
macrophages), and 3+ (multiple CD68+ macrophages). Membranous β-catenin 
(AKB and VT) and membranous E-cadherin (VT and AS) were evaluated for 
staining intensity according to a four-tiered system: 0 (negative, no detectable 
staining), 1+ (weak, faint discontinuous membrane staining), 2+ (moderate and 
continuous membrane staining), 3+ (strong and continuous membrane staining). 
Cytoplasmic β-catenin (AKB and VT), cytoplasmic vimentin (AKB & AS) and 
cytoplasmic periostin (VT & AS) were scored due to staining intensity: 0 
(negative), 1+ (weak), 2+ (moderate), and 3+ (strong). The statistical analysis was 
performed with the SPSS 16.0 software for Windows (IBM). 
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Quantitative real time PCR  
RNA was isolated from F9-tumors as described elsewhere. cDNA was 
synthesized using the Omniscript reverse transcriptase kit (Qiagen). Q-PCRs were 
carried out using the LightCycler 480 instrument (Roche Diagnostics). PCR 
program: 95ºC, 5 min, 45 cycles of 10 s 95ºC, 25 s annealing and 15 s 72ºC. 
Primers were obtained from Microsynth, Switzerland, (primer sequences and 
annealing temperatures, see supplementary Table S1). The PCR-products were 
analyzed on 1.5% agarose gels. Expression of all target genes was normalized to 
β-actin and GAPDH levels. All samples were run in duplicates of n=5-6/per group. 
Fold change was calculated using the Pfaffl equation (Pfaffl, 2001).  
 
TOPFLASH reporter assay  
The TOPFLASH reporter assay was established as previously described 
(Korinek et al. 1997). The fold value was calculated as TOPFLASH/FOPFLASH, 
where TOPFLASH is the plasmid expressing luciferase downstream of three wild 
type β-catenin/Tcf binding sites, and FOPFLASH is the plasmid with mutated 
binding sites. Renilla pRL SV40 was included as transfection control. Luciferase 
was detected using the Dual Glo Luciferase detection kit (Promega). The samples 
were analyzed an SPECTRAmax® GEMINI XS instrument (Molecular Devices). 
The cells were transfected two days prior to luciferase readout using a standard in-
house transfection protocol. 
Western blots  
F9- and NMuMG-cells were lysed (1% NP-40, 100 mM ortho vanadate, 100 
mM 3-indoleacetic acid (IAA), 100 mM phenylmethylsulfonylfluoride (PMSF)) at 
annotated time points and snap frozen in liquid nitrogen. Frozen tumors were 
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soaked in lysis buffer and homogenized using an Ultra Turrax T8 homogenizer 
(IKA-Werke). Protein concentration was determined by Bradford analysis (Biorad). 
The blots were quantified using ImageQuant5.2 software (Amersham 
Biosciences). Protein expression was normalized to β-actin. 
 
Graphs and statistical calculations were performed with the GraphPad Prism 5 
software unless otherwise noted. 
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8. List of abbreviation  
 
APC: Adenomatosis polyposis coli 
Arp2/3: Actin related protein 2/3 complex 
ATP: Adenosine triphosphate 
bHLH: Basic helix-loop-helix 
CAF: Cancer associated fibroblasts 
COX-2: Cyclo-oxogenase 2 
CSF-1: Colony stimulating factor-1 
CSFR-1: Colony stimulating factor receptor-1 
ECM: Extra cellular matrix 
EGF: Epidermal growth factor 
EGFR: Epidermal growth factor receptor 
EMT: Epithelial to mesenchymal transition 
F9-CM: F9-cell conditioned medium 
GSK3β: Glycogen synthase kinase-3β 
HIF-1: Hypoxia inducible factor-1 
HGF: Hepatocyte growth factor 
iNOS: Inducible nitric oxide synthase 
INF-γ: Interferon-γ 
LPS: Lipo-polysaccharide 
M1: Pro-inflammatory macrophages, M1 phenotype 
M2: Pro-tumor macrophages, M2 phenotype 
M-CM: Macrophage conditioned medium 
MET: Mesenchymal to epithelial transition 
MMP: Matrix metalloproteinase 
N1: Pro-inflammatory neutrophils, N1 phenotype 
N2: Pro-tumor neutrophils, N2 phenotype 
N-CM: NMuMG-cell conditioned medium 
NK-cells: Natural killer cells 
NFκB: Nuclear factor-κB 
PI3K: Phosphoinositide-3-kinase 
PLC: Phospholipase Cγ 
q-PCR: Quantitative polymerase chair reaction 
ROI: Reactive oxygen intermediates  
ROS: Reactive oxygen species 
RTK: Receptor tyrosine kinase 
SC: Spearman correlation 
SDF-1: Stromal derived factor-1 
SEM: Standard error of mean 
TAM: Tumor associated macrophage 
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TGF-β: Transforming growth factor-β 
TGFR-β: Transforming growth factor-β receptor 
TNF-α: Tumor necrosis factor-α 
Tregs: T-regulator cells (Th2 response) 
uPA: Uro-kinase plasminogen activator 
uPAR: Uro-kinase plasminogen activator receptor 
VEGF: Vascular endothelial growth factor 
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9. Gene list 
Arp2/3: Actin related protein 2/3 complex 
Cd44: CD44 
Cd68: CD68 
Cdh1: E-cadherin 
Cdh2: N-cadherin 
Ctsb: Cathepsin B 
Ctsh: Cathepsin H 
Col18a1: Procollagen 18  
CSFR-1: Colony stimulating factor receptor-1 
Egf. Epidermal growth factor 
Erdnrb: Endothelin receptor B  
Fn: Fibronectin 
Lmna: Lamin A 
Lamb: Laminin b 
Mmd : Monocyte to macrophage differentiation factor 
MMP14: Matrix metalloproteinase 14  
Mrc : Mannose receptor C  
Tgfβ1,2: Transforming growth factor 1 and 2 
Thbs1: Thrombospondin 1  
Twist1: Twist 
Snai1: Snail 
Stmn1: Stathmin 1 
Vim: Vimentin 
Wnt5a: Wnt 5a 
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Supplementary figure S1 
 
 
Fig. S1. Protein expression analysis of F9- and NMuMG-cells cultured in 
F9/N-CM and M-CM. A. Western blotting analysis of E-cadherin, β-catenin and 
active β-catenin expression by F9-cells cultured in F9-CM or M-CM. B. Western 
blotting analysis of E-cadherin, β-catenin and active β-catenin expression by 
NMuMG-cells cultured in N-CM or M-CM 
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Supplementary figure S2 
 
 
Fig. S2. Wnt5a gene expression in F9-teratocarinomas. A. Standard curve 
generated from 4 dilutions of a Wnt5a overexpressing cDNA template. B. PCR 
products from a Wnt5a template, evaluated on a 1.5% agarose gel (dilutions: 1, 
1:5, 1:10 and 1:15). C. PCR products obtained from the reaction using template 
from 5 control F9-tumors, 5 clodrolip treated F9-tumors and 2 Wnt5a 
overexpressing control templates. GAPDH primers were included in the reaction 
as control for the reaction and gel loading. 
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Supplementary figure S3 
 
 
Fig. S3. rTGF-β1 induces an EMT phenotype in NMuMG-cells in vitro. 
Immunofluorescence analysis of E-cadherin, β-catenin, vimentin and fibronectin 
(all in red) expression in NMuMG-cells cultured in DMEM +/- rEGF (50ng/ml) or 
DMEM +/- rTGF-β1 (2ng/ml) for 13 days. Scale bar=0.02 mm. Nuclei were stained 
with DAPI. 
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Supplementary figure S4 
 
 
Fig. S4. Recombinant EGF and TGF-β1 activates the MAPK pathway in F9- 
and NMuMG-cells. Western blotting analysis of MAPK activation (MAPK 42/44) in 
F9- and NMuMG-cells after stimulation with rEGF (50ng/ml) and rTGF-β1 (2ng/ml) 
for 5, 15 and 30 min. Transcription Factor II H (TFIIH) was included as loading 
control. 
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Supplementary figure S5 
 
Fig. S5. Neutralization of TGF-β abrogates M-CM induced EMT in vitro. 
Immunofluorescence analysis of E-cadherin, β-catenin, vimentin and fibronectin 
(all in red) expression in NMuMG-cells cultured for 24 hours and 13 days in M-CM 
neutralized for TGF-β. Scale bar=0.02 mm. Nuclei were stained with DAPI. 
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Supplementary figure S6 
 
 
 
Fig. S6. rTGF-β1 is not a potent chemoattractant for F9- and NMuMG-cells in 
vitro. Fold invasion of F9- (left) and NMuMG-cells (right) in response to DMEM +/- 
rTGF-β (2ng/ml), (48 hours, 1% Matrigel); n=2, p> 0.05, unpaired t-test, bar = ± 
SEM. 
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Appendix 2. A. Quality control of mRNA isolated from two control (upper panel) 
and two clodrolip treated (lower panel) F9-teratocarcinoas (QC was performed 
using the Experion RNA Std Sense Analysis kit/Bioanalyser). B. Correlation plot of 
the four F9-tumors (two controls, two clodrolip treated) included in the final micro 
array analysis. Dark squares indicates low similarity in gene expression between 
the tumors, and light squares indicates high similarity in gene expression. 
 
A 
A
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Abstract: 
Purpose: Tumor progression is highly influenced by stromal components. Several 
stromal-derived factors contribute to tumor progression by inducing epithelial-
mesenchymal transition (EMT). As EMT promotes tumor cell invasion, therapies 
abrogating it can significantly improve cancer management. Here, we characterize 
tumor associated macrophages (TAMs) as key stromal regulators of tumor cell EMT 
in vivo and in vitro. 
Experimental design: Tumor cell expression of EMT-associated markers was 
analyzed in murine F9-teratocarcinomas infiltrated by - or depleted of - TAMs. In vivo 
depletion of TAMs was performed using clodronate-liposomes. TAM-induced EMT 
was further characterized in two murine cell lines, the F9- and the mammary gland 
NMuMG cell line, using a conditioned medium culture approach. The clinical 
relevance of our findings was evaluated in a tissue microarray platform representing 
491 NSCLC patients.   
Results: Gene expression analysis of F9-teratocarcinoma tumors revealed a 
negative correlation between TAM-depletion and mesenchymal marker expression. 
In vitro, long term exposure of F9- and NMuMG-cells to macrophage-conditioned 
medium led to decreased expression of the epithelial adherence protein E-cadherin, 
activation of the EMT-mediating β-catenin pathway, increased expression of 
mesenchymal markers and increased invasive properties. In a candidate based 
screen, macrophage-derived TGF-β was identified as the main inducer of this EMT-
associated phenotype. Lastly, histopathologic evaluation of 491 NSCLC patient 
samples identified a positive correlation between intra-tumoral TAM densities, 
mesenchymal tumor phenotype and high tumor grade. 
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Conclusions: Data presented here identify TAMs as key regulators of EMT-
promoted tumor progression and contribute novel information to the discussion on 
therapeutic targeting of the tumor stroma. 
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